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ABSTRACT 
Background: The implementation of routine and mass vaccination programmes allowed 
the control of once life-threatening diseases like diphtheria and tetanus. Immunisation benefits 
were so satisfying that today we are facing the consequences of its own success. As parents 
have become less familiar with these diseases, they have become more concerned about the 
safety and necessity of vaccines.  
This study aims to analyse adverse events following immunisation in the Portuguese 
paediatric population (2012 – 2016), explore vaccine trends in Portugal and compare the 
records from Portugal and The Netherlands. Additionally, the factors and reasons for vaccine 
hesitancy in high-income countries are addressed through a systematic review. 
Methods: We conducted a retrospective study on adverse drug reactions in paediatrics 
to DTPa and MMR vaccine in Portugal, from 2012 to 2016. Public information on vaccine 
coverage and vaccine preventable disease cases in Portugal and in The Netherlands, was 
explored and compared. We conducted a systematic review on the factors behind vaccine 
hesitancy among parents in high-income countries. 
Results: From 2012 to 2016 a total of 591 ADR reports, concerning Portuguese paediatric 
individuals exposed to DTPa, and/ or to MMR vaccines, were analysed. The system organ 
class most frequently involved in ADR reports was general disorders and administration site 
conditions. In Portugal, the national immunization program participation ranges from 96,1% to 
99,1% vaccine coverage. In this study, it is possible to observe vaccination coverage decline 
over the selected cohorts in the Netherlands. Vaccine safety was the most recorded factor of 
vaccine hesitancy in the systematic review. 
Conclusions: Adverse drug reaction reporting to vaccines in the Portuguese paediatric 
population is slightly decreasing over the years. Vaccination coverage in Portugal is very high. 
In The Netherlands vaccination coverage is decreasing. In Portugal, vaccine preventable 
disease cases in the paediatric population is consistently lower than in The Netherland. 
Parental risk perception of adverse drug reactions to vaccines is playing an important role on 
parental compliance with the national immunization program in high-income countries, which 
may lead to vaccine hesitancy or vaccine refusal.  
Keywords: Immunization, Adverse Drug Following Immunization, Vaccine Coverage, 
Vaccine Preventable Diseases, Vaccine Hesitancy 
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RESUMO 
Introdução: A imunização é considerada a medida de saúde pública mais bem-
sucedida e com melhor eficácia, logo após a água potável. A implementação dos programas 
de vacinação em massa permitiu a erradicação da varíola, a eliminação da poliomielite em 
diversas regiões do globo e o controlo de muitas doenças contagiosas, anteriormente mortais, 
tais como a difteria e o tétano.  
Qualquer substância capaz de produzir um efeito terapêutico, não se encontra isenta 
de produzir efeitos não desejados ou efeitos adversos, nenhum medicamento que seja 
farmacologicamente eficaz é completamente desprovido de riscos. A reação adversa a 
medicamentos é uma significante causa de mortalidade e morbilidade, especialmente na 
população pediátrica, e é fortemente associada a um importante custo económico com a 
saúde. Todas as vacinas autorizadas no mercado Europeu são rigorosamente testadas e 
monitorizadas, com elevados padrões de segurança, eficácia e qualidade. Milhões de vacinas 
são administradas em crianças anualmente, as reações adversas graves são incomuns e as 
mortes causadas pela administração de vacinas são muito raras. O Sistema Nacional de 
Farmacovigilância é responsável pela deteção, registo e avaliação das reações adversas, com 
o objetivo de determinar a incidência, gravidade e causalidade com os medicamentos, 
baseadas no estudo sistemático e multidisciplinar dos efeitos dos medicamentos. A 
notificação espontânea é um instrumento muito importante na monitorização da 
farmacovigilância, o principal objetivo da notificação espontânea é sinalizar novas reações 
adversas, que não foram encontradas antes da comercialização do medicamento, o mais 
rapidamente possível. O Sistema Nacional de Farmacovigilância é coordenado pelo Grupo de 
Gestão de Risco do Medicamento do INFARMED, I.P., quando a notificação de uma reação 
adversa grave é recebida pelo INFARMED, toda a informação é avaliada por uma equipa 
especialista em segurança do medicamento, para verificar se a reação adversa pode ter 
ocorrido devido à administração da vacina. Em Portugal, os médicos, farmacêuticos, indústria 
e utentes estão autorizados a reportar reações adversas a medicamentos às unidades de 
farmacovigilância.  
O Programa Nacional de Vacinação português está disponível para todos os cidadãos 
que se encontrem presentes em Portugal, incluindo imigrantes legais ou ilegais. Estão 
incluídas onze vacinas, que são recomendadas a todas as crianças com idades inferiores a 
18 anos. O objetivo do calendário de vacinação recomendado é atingir a melhor proteção na 
idade mais adequada e o mais cedo possível, porque é no primeiro ano de idade que a criança 
é mais vulnerável a doenças infeciosas.  
Apesar da cobertura vacinal em Portugal ser considerada elevada e os casos de 
doenças estarem controlados, as autoridades nacionais estão atentas a movimentos anti 
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vacinação que estão a emergir na Europa, de que é exemplo a Holanda. A Holanda possui 
grupos já identificados de pais que recusam a vacinação, incluindo protestantes que residem 
na região do Cinturão Bíblico. Os membros das Congregações Reformadas acreditam que a 
vacinação é contra os preceitos de Deus. Os Antroposóficos acreditam que experienciar 
algumas doenças infeciosas contribui para reforçar o corpo e a mente. 
 O Programa Nacional de Vacinação holandês inclui as mesmas vacinas que em 
Portugal. Apesar da cobertura vacinal na Holanda ser considerada elevada, tem-se vindo a 
observar nos últimos anos um declínio. Estas flutuações foram inicialmente observadas a nível 
regional, no entanto são agora comuns a toda a nação. Apesar de uma variedade de fatores 
desconhecidos poderem estar na origem deste declínio, a hesitação à vacinação por parte 
dos pais pode constituir um importante determinante neste campo.  
As vacinas são geralmente administradas em sujeitos saudáveis, normalmente em 
populações vulneráveis, como é o caso das crianças, pelo que as reações adversas têm um 
grande impacto na aceitação da imunização assim como na avaliação do benefício-risco. As 
atitudes, experiências e contexto social dos pais são determinantes na decisão de vacinar ou 
não a criança. O conhecimento que os pais têm face às doenças que podem ser prevenidas 
por vacinas, influenciam a sua perceção relativamente à gravidade da doença e à 
probabilidade das suas crianças virem a ser infetadas. Indivíduos hesitantes à vacinação 
demonstram níveis de indecisão variáveis sobre vacinas específicas ou sobre a vacinação em 
geral. Podem aceitar todas as vacinas, mas permanecer preocupados quanto à sua 
administração, alguns pais podem recusar ou adiar algumas vacinas, mas aceitar outras, 
outros indivíduos podem recusar todas as vacinas. O comportamento dos indivíduos 
hesitantes à vacinação é complexo e os determinantes da hesitação vacinal são altamente 
variáveis ao longo do tempo, espaço e vacina. 
Os benefícios da imunização foram tão satisfatórios que hoje enfrentamos as 
consequências do seu próprio sucesso. À medida que os pais foram ficando menos 
familiarizados com estas doenças, começaram a ficar mais atentos e preocupados quanto à 
segurança e necessidade das vacinas. Isto levanta uma grande preocupação quanto ao futuro 
do Programa Nacional de Vacinação, se a cobertura vacinal continuar a descer, não seremos 
capazes de manter a imunidade de grupo e consequentemente a população ficará suscetível 
às doenças prevenidas por vacinas. 
Este estudo pretende analisar os casos de reações adversas a vacinas na população 
pediátrica portuguesa (2012 – 2016), explorar a tendência vacinal em Portugal e comparar os 
indicadores de cobertura vacinal de Portugal e da Holanda. Adicionalmente, através de uma 
revisão sistemática da literatura, serão investigados os fatores que explicam a hesitação em 
países industrializados. 
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Métodos: Foi realizada uma análise retrospetiva sobre das adversas (RAMS) às 
vacinas DTPa e VASPR ocorridas na população pediátrica, em Portugal, no período entre 
2012 e 2016. Foi analisada a informação publicada sobre a cobertura vacinal e o número de 
casos de doenças prevenidas por vacinas em Portugal e na Holanda. Foi realizada uma 
revisão sistemática de literatura sobre os fatores etiológicos da hesitação à vacinação em 
países industrializados. 
Resultados: Desde 2012 a 2016 um total de 591 notificações de reações adversas às 
vacinas DTPa e VASPR, na população pediátrica portuguesa, foram analisadas. A faixa etária 
com maior número de notificações foi entre os 3 anos (inclusive) e os 12 anos (exclusive). O 
código ATC mais frequentemente envolvido nas notificações de reação adversa foi o J07CA02 
vacina contra a difteria, o tétano, a tosse convulsa e a poliomielite. A classe de sistema de 
órgãos mais prevalente nas notificações foi transtornos gerais e condições do local de 
administração. Em 55,33% as reações adversas foram consideradas graves, 71,06% dos 
indivíduos com a reação adversa recuperaram completamente. A maior percentagem de 
reações adversas foi reportada pelo enfermeiro.  
Em Portugal, a cobertura vacinal do programa nacional de vacinação varia entre 96,1% 
e 99,1%, o que de acordo com este estudo, contrasta com os valores de cobertura vacinal 
apresentados pela Holanda, que variam desde 19.7% a 96.1%. Este estudo evidencia 
também, um declínio na cobertura vacinal das coortes selecionadas na Holanda que se tem 
vindo a repetir durante os últimos anos.  
Foram diversos os fatores identificados como estando associados à hesitação à 
vacinação. Foram identificados como fatores respetivamente, as características específicas 
dos pais, fatores relacionados com as vacinas e fatores relacionados com a doença. O fator 
mais referido na revisão sistemática de literatura foi a segurança vacinal. 
Conclusão: A notificação de reações adversas a vacinas na população pediátrica 
portuguesa está a diminuir ao longo dos anos. A cobertura vacinal em Portugal é elevada. Na 
Holanda, a cobertura vacinal está a diminuir. Em Portugal, o número de casos de doenças 
prevenidas por vacinas é substancialmente inferior aos dados registados na Holanda. A 
perceção de risco dos pais face às reações adversas a vacinas constitui um importante fator 
no cumprimento do plano nacional de vacinação nos países industrializados, o que pode gerar 
hesitação à vacinação ou mesmo a recusa vacinal.  
Palavras-chave: Imunização, Reação Adversa, Cobertura Vacinal, Doenças 
Prevenidas por Vacinas, Hesitação à Vacinação 
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1. CHAPTER 1 – INTRODUCTION 
1.1. Immunisation 
Immunisation is the most effective and successful public health intervention in the world 
for saving lives and promoting good health, right after clean water (1).  
Vaccination began in 1796 with Edward Jenner’s experiments (2). Jenner tested whether 
the deliberate inoculation of cowpox material would prevent the pustules caused by 
subsequent inoculation, which would be a sign of protection against the disease (3). The 
success of this experiment led Jenner to speculate that ‘the annihilation of the smallpox, the 
most dreadful scourge of the human species, must be the final result of this practice’ (3). 
Rabies vaccine was developed using the principle of attenuation by Pasteur and first 
tested in man in 1885 (4). This vaccine was based on material obtained from infected rabbit 
brain attenuated by drying, an uncertain process, and vaccines prepared in this way frequently 
caused serious side effects (4). Most human rabies vaccines are now based on inactivated 
virus grown in tissue culture (4). Acquisition of the ability to grow viruses in tissue culture led 
to the development of attenuated vaccines against measles and poliomyelitis in the 1950s and 
the 1960s (4). Many other vaccines have been developed using the principle of attenuation, 
including rubella, influenza, rotavirus, tuberculosis and typhoid vaccines (4). 
By the late 1959s, the majority of children in developed countries were receiving routine 
vaccination with tetanus toxoid, diphtheria toxoid and a killed pertussis vaccine (DTP) and polio 
vaccine and, in some countries, vaccination against tuberculosis (4). By the 1960s, the vast 
majority of deaths and severe illnesses attributable to vaccine preventable diseases were 
occurring in children in the developing world (4). At this time, about one-third of African children 
did not reach the age of 5 years and infectious diseases, particularly measles, accounted for 
a substantial proportion of these deaths (4). 
While the concept of vaccination spread rapidly throughout the world, it was not until the 
Intensified Smallpox Eradication Program of 1967 that much progress was made in controlling 
the disease on a large scale (5). Massive vaccination campaigns occurred worldwide and were 
combined with sophisticated surveillance systems to detect outbreaks (5).  
The implementation of routine and mass vaccination programmes has led to the 
eradication of smallpox, the last naturally occurring case of smallpox was in 1977, this 
infectious disease was known for plaguing millions of children globally (6–8). And to the 
elimination of poliomyelitis in many regions of the world, according to WHO the European 
Region was declared free of endemic polio in 2002 (9). Poliomyelitis is a devastating disease 
which paralyses children for life and until now, we did not find its cure (10). But it’s been proven 
by experience that the vaccine against poliovirus is very effective and protects children for life 
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(10). In 1988 more than 350 000 children were paralysed by the disease, in more than 125 
countries (10). In 2015 type 2 poliovirus was considered globally eradicated and there was a 
3-year absence of type 3 poliovirus (9). Wild poliovirus type 1 is now cornered in only two 
remaining endemic countries – Afghanistan and Pakistan (9). However, in 2015 two cases of 
circulating vaccine-derived poliovirus were detected in the European Region, in Ukraine (9). 
This raises concerns over the safety of the population, high immunization coverage in all 
countries is crucial to keep the region polio free (9).   
The implementation of routine and mass vaccination programmes allowed as well the 
control of once life-threatening diseases like diphtheria and tetanus (5–8). 
A growing knowledge on immunology and the development of new technologies 
(recombinant DNA and conjugation of polysaccharides) to produce vaccines has increasingly 
influenced vaccine design in the past century and allowed the introduction of immunization 
programmes against hepatitis B, Haemophilus influenzae b, and pneumococcal and 
meningococcal diseases in many countries of the world (6,11).  
Approximately 13 million of people in the WHO European Region are chronically infected 
with hepatitis B, leading to approximately 60 000 deaths per year from hepatitis-B-related liver 
cancer and cirrhosis (9). The prevention and control of this disease can be tracked through 
integrated programmes (9). Though national policies vary widely, 47 of 53 (87%) countries in 
the WHO European Region have successfully implemented universal hepatitis B immunization 
(9). This will lead in the long term to reduction of incidence and mortality due to acute hepatitis 
B, and consequences of chronic infection such as liver cirrhosis and hepatocellular carcinoma 
(9). 
The efforts of countries and international agencies to increase vaccination coverage have 
produced notable results (6).  
1.2. Vaccines  
After a great scientific advance in terms of efficacy and safety, vaccines are nowadays 
considered to be an heterogeneous class of medicinal products containing immunogenic 
substances capable of inducing specific, active and protective host immunity against infectious 
disease (12). When these immunogenic substances are introduced in the organism it triggers 
a complex cascade of biological events, similar to real infection caused by an infectious agent 
which culminates in the production of antibodies against the antigen and the establishment of 
protective immunity and immunological memory against the pathogen (13,14).  
During the first interaction of the immune system with the pathogen, lymphocyte activation 
and generation of memory cells are slow (3 to 14 days) and unspecific (15,16). Vaccination is 
used to induce this primary response of the immune system to a specific pathogen, in a secure 
and controlled environment (15,16). Specific memory cells to that pathogen are produced after 
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vaccination uptake and the organism will be protected against secondary infections caused by 
the same infectious agent in the vaccine (15,16).  
When the immune system is exposed to an antigen against which there was a primary 
response mediated by a vaccine or disease, there is already a population of B-lymphocytes 
capable of recognizing this specific antigen due to the memory cells that were generated during 
the primary response (15,16). Memory B cells rapidly divide to produce plasma cells and a 
large amount of antibodies, the dose of antigen required to induce the response is lower than 
in the first response (15,16). So, the secondary response provides better protection than the 
primary response since the time required to start producing antibodies is lower (hours to few 
days) and because the amount of antibodies produced is much higher (15,16). The memory 
response also includes the formation of new memory B cells that protect the organism against 
further exposure to the antigen (15,16). Memory B cells can last for many years and in some 
cases a lifetime (15,16). 
Infectious diseases are usually communicable diseases caused by an external agent such 
as virus, bacterium or parasite (14).  
Vaccines for human use include one or more of the following: microorganisms inactivated 
by chemical and/or physical means that retain appropriate immunogenic properties; living 
microorganisms that have been selected for their attenuation whilst retaining immunogenic 
properties; antigens extracted from microorganisms, secreted by them or produced by 
recombinant DNA technology; chimeric microorganisms; antigens produced in vivo in the 
vaccinated host following administration of a live vector or nucleic acid or antigens produced 
by chemical synthesis in vitro. The antigens may be in their native state, truncated or modified 
following introduction of mutations, detoxified by chemical or physical means and/or 
aggregated, polymerized or conjugated to a carrier to increase immunogenicity. Antigens may 
be presented plain or in conjunction with an adjuvant, or in combination with other antigens, 
additives and other excipients (12). 
Some of these antigens are weakly immunogenic and require the presence of adjuvants 
for the induction or enhancement of an adequate immune response (17,18). Adjuvants are 
compounds that enhance the immunogenicity of highly purified or recombinant antigens, it can 
be used thus to reduce the amount of antigen or the number of immunizations needed for 
protective immunity, to improve the efficacy of vaccines in newborns, the elderly or 
immunocompromised people, or as antigen delivery systems for the uptake of antigens by the 
mucosa (17,18). 
Nowadays, vaccine adjuvants include aluminium saults, oil-in-water emulsions, 
monophosphoryl lipid A (MPL) and virosomes (19). 
Aluminium adjuvants used in some vaccines include aluminium hydroxide, aluminium 
phosphate, alum (potassium aluminium sulphate), or mixed aluminium salts (20). Aluminium 
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adjuvant containing vaccines have a demonstrated safety profile of over six decades of use 
and have only uncommonly been associated with severe local reactions (20). The Food and 
Drug Administration (FDA) analysis indicates that the body burden of aluminium following 
injections of aluminium-containing vaccines never exceeds safe USA regulatory thresholds 
based on orally ingested aluminium even for low birth-weight infants (21). The most common 
source of exposure to aluminium is from eating food or drinking water (20).  
Thimerosal is a mercury-containing organic compound, it is metabolized or degraded to 
ethylmercury and thiosalicylate (22). Since the 1930s, it has been widely used as a 
preservative in a number of biological and drug products, including many vaccines, to help 
prevent potentially life threatening contamination with harmful microbes (22). Thimerosal 
concentration as a preservative in a vaccine is 0.01%, which contains approximately 25 
micrograms of mercury per 0.5 mL dose (22). For comparison, this is roughly the same amount 
of elemental mercury contained in a 85 gram can of tuna fish, although the bioavailability of 
mercury in the second case is lower (22). 
The use of mercury-containing preservatives has declined in recent years due to the 
development of new products formulated into single-dose presentations that do not require 
preservatives (22). In Portugal, vaccines used in the National Immunization Program do not 
contain thimerosal (23).  
1.3. National Immunisation Program 
National Immunisation Programmes (NIP) adopted worldwide are important tools to 
protect the population against infectious disease (24). NIP are universal and delivered to every 
citizen from birth, free of charge (24).  
The risk of contracting an infection caused by a pathogen is mainly related to 3 factors: 
the number of infected subjects in a population who are able to transmit the pathogen; the 
amount and type of contact between the ones who transmit and the ones who receive the 
pathogen; and the infectiousness of the pathogen (25). So, in order to control and eliminate 
vaccine-preventable diseases (VPD) high vaccine uptake is crucial (25). Vaccination not only 
provides direct individual protection, it also provides indirect population effects, protection of 
unvaccinated people in the population (25). If a sufficient proportion of a population has been 
vaccinated, protection is also provided to those who have not been vaccinated, for example 
due to a medical condition, this protection is known as herd immunity (26). This means that 
the success of any immunisation programme depends on meeting herd immunity levels to 
prevent local outbreaks and epidemics of the diseases it is targeting (1). 
In the 1950s and 1960s Portugal was facing high mortality levels caused by tetanus and 
diphtheria diseases, causing 2625 and 1457 deaths respectively from 1956 to 1965 (27). 
Tetanus is a serious disease caused by an endotoxin produced by Clostridium tetani (28). 
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Tetanus natural infection does not confer immunity to the host, immunity can only be achieved 
by tetanus vaccination with tetanus toxoid (28). It is not possible to obtain herd protection from 
tetanus vaccination, so the only way to eliminate the disease is to adequately vaccinate 100% 
of the population (28). In 1962 tetanus and diphtheria vaccines become compulsory for all 
individuals living in Portugal, the decree-law n.º 44198, 20th February also specified that no 
individual under 10 years old could be accepted to educational establishments, and no 
individual could be accepted to public functions unless they prove to be vaccinated against 
diphtheria and tetanus (29). After diphtheria and tetanus vaccines have been made 
compulsory, there was a significant drop in mortality rate, from 1999 to 2008 tetanus caused 
30 deaths and diphtheria caused 0 deaths (27).  
In 1965 NIP was initiated in Portugal with a mass campaign against poliomyelitis, this was 
a devastating disease which caused child paralysis and death (30).  
In 1966 Portugal’s NIP included polio, tuberculosis, smallpox, pertussis, diphtheria and 
tetanus vaccines (30). Since 1952 there have been no cases of smallpox in Portugal, so in 
1977 Decree-Law n.º 19/77 was made public and smallpox vaccine was suspended (31). NIP’s 
effectiveness is proven by the eradication of smallpox in 1980, the elimination of poliomyelitis 
throughout all European Region in 2002 and by the control of diphtheria, measles and neonatal 
tetanus in Portugal (30).  
In 1974 measles’ monovalent vaccine was included in the NIP, later in 1987 the 
monovalent vaccine was substitute by MMR vaccine which combined measles, mumps and 
rubella in the same vaccine (32). Initially, vaccine coverage was not enough to prevent an 
epidemy in 1987-89 with approximately 12.000 notified cases and 30 deaths (32). Europe was 
facing measles outbreaks in several countries, so in 2008 and 2011 complementary 
vaccination measures were reactivated and the epidemiological surveillance of measles was 
reinforced (32). Measles vaccine coverage in 2015 was 98% for 2014, 2013 and 2001 cohorts 
(33). Although vaccine coverage is very high in Portugal, in April 2017 there was a measles 
outbreak with 46 notified cases, 21 cases were confirmed and one adolescent died, 57% of 
confirmed cases occurred in unvaccinated people (34). This raises a big concern over the 
importance and necessity of immunising children according to NIP. 
The Portuguese NIP includes eleven vaccines which are recommended to every child 
under 18 years old, against: hepatitis B (HBV), diphtheria, tetanus (Td), pertussis (DTPa), 
poliomyelitis (IPV), infections caused by Haemophilus influenzae serotype b (Hib), 
Streptococcus pneumoniae (13 serotypes), Meningococcal disease C (MenC), measles, 
mumps and rubella (MMR) (35). It is also recommended the vaccine against Human 
Papillomavirus to girls (35).  
Since June 2016, Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis is no 
longer universally recommended from birth, it is now recommended just to risk groups (35). 
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BCG is effective in preventing severe, rapidly progressive tuberculosis in children but does not 
prevent infection or re-activation of latent disease, and has had little impact on tuberculosis 
disease control worldwide (36).  
HBV is the first recommended vaccine to be administered, the vaccine is administered in 
the maternity to the new-born (35). At 2-months old it is recommended administration of DTPa 
1st dose, Hib, IPV and HBV 2nd dose – hexavalent vaccine DTPaHibIPVHBV (35). It is also 
administered the 1st dose of the combined vaccine against Streptococcus pneumoniae 13 
serotypes – Pn13 (35). At 4-months old it is recommended DTPa, Hib and IPV 2nd dose – 
combined in a pentavalent vaccine DTPaHibIPV (35). And it is administered Pn13 2nd dose 
(35). At 6-months old it is recommended DTPa, Hib, IVP and HBV 3rd dose – hexavalent 
vaccine DTaPaHibIPVHBV (35). At 12-months old it is recommended Pn13 3rd dose, MenC 
and MMR 1st dose (35). At 18-months old it is recommended DTPa, IPV and Hib 4th dose  - 
pentavalent vaccine DTPaHibIPV (35). At 5 years old it is recommended DTPa and IPV 5th 
dose – tetravalent vaccine DTPaIPV; and MMR 2nd dose (35). At 10 years old, it is 
recommended tetanus and diphtheria – Td, booster dose. It is recommended to girls 2 doses 
of HPV vaccine – HPV9 (0,6 months schedule) (35).  Booster doses of tetanus and diphtheria 
are recommended at 10, 25, 45, 65 years old and every 10 years thereafter (35). 
The evaluation of NIP is presented through the rates of vaccination coverage, the 
percentage of immunised population (serologic data) and the impact of vaccination on target 
disease (35). Although vaccine coverage in Portugal is considered high and the diseases are 
controlled, national authorities are aware of anti-vaccination movements which are emerging 
in the European Region, as for example in the Netherlands (30,37). To maintain this success, 
continued high coverage and trust in vaccination by the population is of the utmost importance 
(37). 
The National Immunization Program in the Netherlands includes vaccination against the 
same twelve infectious diseases as it happens in Portugal (diphtheria, poliomyelitis, pertussis, 
tetanus, Haemophilus influenzae type b, meningococcal group C disease, measles, mumps, 
rubella, hepatitis B, pneumococcal disease, and cervical cancer caused by human papilloma 
virus) (38). All children below the age of 13 years are eligible to receive vaccinations included 
in the NIP (37). Routine vaccination started in the Netherlands in 1957, it is non-mandatory 
and free of charge (37). Incidence rates of nearly all diseases targeted by the Dutch NIP have 
been reduced successfully (37).  
Although a variety of unknown factors may be behind vaccine coverage decline, parental 
vaccine hesitancy may be playing an important role in this field. It is important to understand 
what are the reasons and beliefs behind parent’s decision to refuse one or more vaccines 
included in the NIP, so that we can find tools to increase vaccine confidence and maintain high 
vaccination coverage. Understanding parent’s willingness to vaccinate their child, and the 
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reasons behind their choice is complex (26). Some parents may unquestioningly accept or 
reject all vaccination programme or just refuse some vaccines, while others experience 
uncertainty, which may delay or result in rejection of immunisation and some experience 
barriers that prevent immunisation (26). 
1.4. Vaccine Evaluation  
Any substance that is capable of producing a therapeutic effect can also produce 
unwanted or adverse effects (39). No drug which is pharmacologically effective is entirely 
without hazard (40). 
A higher standard of safety is expected of vaccines, since vaccines are generally given to 
healthy subjects to prevent disease and not to cure it. Public tolerance of adverse reactions 
related to products given to healthy persons, especially risk groups – healthy infants and 
children, is substantially lower than for reactions to products administered to people who are 
already sick (41). This lower tolerance of risk for vaccines translates into a need to investigate 
the possible causes of very rare adverse events following vaccinations (41). 
All authorized vaccines in the European market are rigorously tested and monitored, have 
high safety, efficacy and quality standard and it is also required certification to every batch 
manufactured prior to its distribution (35,42). Vaccines are among the safest medicinal product 
in use (42). Millions of vaccinations are administered to children each year (42). Serious 
adverse reactions are uncommon and deaths caused by vaccines are very rare (42).  
ADR are a significant cause of morbidity and mortality especially among young children 
and are associated with significant healthcare costs (43). Most ADR are due to common drug 
used in everyday practice like antibiotics and nonsteroidal anti-inflammatory drugs, with up to 
98% being considered preventable (43).  
The regulation of vaccines can be divided into three stages: developmental, licensure and 
post-licensure (44).  
The developmental stage consists of two parts, nonclinical research and development, 
and clinical research and development (44). 
Nonclinical research refers to all in vivo and in vitro testing performed before and during 
the clinical development of vaccines, it includes all aspects of testing product characterization, 
proof of concept/ immunogenicity studies and safety testing in animals conducted prior to 
clinical testing of the product in humans (12). When safety testing in animals is preformed, 
there should be a clear rationale for doing so and the study should be performed in compliance 
with the national and international laws for the protection of laboratory animals, biosafety 
requirements and with good laboratory practice (12). Potential safety concerns for a vaccine 
product include those due to inherent toxicities of the product, toxicities of impurities and 
contaminants, and toxicities that result from interactions between the vaccine components 
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present in the vaccine formulation (12). In addition, the immune response induced by the 
vaccine may lead to toxic side-effects (12).  
Clinical research and development main objective it to accumulate adequate data to 
support initial licensure and appropriate use, it will reflect how much is already known about 
the antigenic components and adjuvants in the vaccine (45). The essential elements of the 
pre-licensure clinical development programmes are: to describe the interaction between the 
vaccine and the host immune response; to identify safe and effective dose regimens and 
schedules; to estimate vaccine efficacy by directly measuring efficacy and/ or to provide 
evidence of vaccine efficacy based on immune responses; to describe the safety profile; and 
to assess co-administration with other vaccines if relevant (45). 
After initial licensure, it is essential to monitor vaccine safety in routine use, studies 
designed to address specific safety issues that were identified as potential concerns from pre-
licensure trials may need to be conducted, it is commonly appropriate to evaluate vaccine 
effectiveness (45). Further trials may be conducted and the data may be used to extend or to 
otherwise modify the use of the vaccine through revision of the prescribing information (45). 
1.5. Pharmacovigilance System 
According to WHO, “Pharmacovigilance is the science and activities related to the 
detection, assessment, understanding and prevention of adverse effects or any other possible 
drug-related problems” (46). The aim of pharmacovigilance is to improve patient care and 
safety related to drug use and medical interventions; contribute to the assessment of benefit, 
harm, effectiveness and risk of medicines; encouraging drug safe, rational and effective use; 
and promote understanding, educational and clinical training in pharmacovigilance and its 
effective communication to the public (46). 
ADR spontaneous notification is an important tool in pharmacovigilance monitoring, the 
main objective of a spontaneous reporting system is to signal new ADRs, that have not been 
recognised prior to marketing, as soon as possible (47). In Portugal, physicians, pharmacists, 
nurses and other healthcare professionals, pharmaceutical industries and patients are able to 
report suspected ADR to the pharmacovigilance system (40). 
ADR notification constitutes the base of the National Pharmacovigilance System (NPS) 
(35). The Portuguese NPS was created in 1992 through the Normative Order 107/ 92 of 27th 
June, its main objective is the early identification of possible safety concerns related to drug 
uptake, including vaccines (35,48,49). In 2000 the decentralization of NPS took place, and the 
Regional Pharmacovigilance Units (RPU) were created, this  made possible a better interaction 
with reporters and a better disclosure of the NPS, contributing to a gradual increase in the 
number of suspected adverse reactions reports over the years (35). The number of ADR 
notifications received by the National Pharmacovigilance System (NPS) has been increasing 
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since 1992, this reflects the results of educational interventions developed by the Regional 
Pharmacovigilance Units (RPU) (40).  
NPS is coordinated by Drug Risk Management Group of INFARMED, I.P., which is 
responsible for the reports monitoring from RPU, Health institutions, pharmaceutical industries, 
health professionals and general public (35). INFARMED reports serious and non-serious ADR 
reported cases occurred in Portugal to the European database for suspected ADR reports – 
EudraVigilance, and to WHO data base (35). Rapid alert European System allows withdraw of 
a vaccine batch which may have safety problems, in just 24 hours from all European Union 
(35). Vaccine Lack of efficacy should be notified as well because it can originate a public health 
issue (35).  
When a serious adverse reaction report is received by INFARMED, all information is 
evaluated by an expert team on drug safety to verify if that adverse reaction may have occurred 
due to vaccine administration (35). Whenever safety issues are identified, adequate measures 
are applied, including information changes in the Summary of Product Characteristics (SmPC) 
and Package Leaflet (PL), elaboration of educational material, national market vaccine 
suspension or removal (35). 
In the European Region, European Medicines Agency (EMA) is responsible for the 
scientific evaluation, supervision and safety monitoring of medicines developed by 
pharmaceutical companies for use in the Europe (50). The Pharmacovigilance Risk 
Assessment Committee (PRAC) is the EMA’s committee responsible for assessing and 
monitoring the safety of human medicines (51). PRAC evaluates the safety signals detected 
in EudraVigilance and may recommend regulatory action as a result (51).  
In the Netherlands, passive surveillance system is managed by the National Centre for 
Pharmacovigilance Lareb, it receives reports of AEFI for all vaccines included in the NIP (38). 
In 2015, Lareb received 1494 reports of a total of AEFI (38). Compared with 2014, this is an 
increase of about 50% (38). Of the reports, 130 were classified as serious (38). Whether this 
was a ‘true’ increase in the occurrence of AEFI or merely an increase in reporting rate is not 
known. 
1.6. Parental Vaccine Hesitancy 
According to Strategic Advisory Group of Experts on Immunisation (SAGE), measles 
and rubella elimination is progressing slower than expected. Since 2010, global measles 
incidence has decreased by 21% from 50 cases per million to 39.3 in 2015 which is 
substantially higher than the global 2015 target (<5 cases per million population) (52). Measles 
outbreaks have occurred in numerous countries as a result of sub-optimal immunisation 
coverage, along with increased susceptibility in older age groups (52).  
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 Parental attitudes, experiences and social grade are influential in determining whether 
a child receives a vaccine (53). Parental knowledge of VPD influence their perception about 
the seriousness of diseases and the likelihood of their children being affected (53). 
According to Evans et al., parents conduct an informal risk-benefit analysis when 
deciding to immunise their child. Since records of vaccine preventable diseases cases are very 
low due to the success of immunisation programs, for some parents, it is easier to accept the 
risk of their child naturally contracting a disease than hurting their child through vaccination 
(54). 
Most parents decide to vaccinate their children although they still have questions or 
concerns about childhood vaccines and the National Immunisation Program (55).  
 For many parents concerns about the safety, necessity and benefits of recommended 
vaccines result in the adoption of an alternative vaccination schedule that differs from the 
childhood vaccination schedule recommended by the Centres for Disease Control and 
Prevention for their children, and sometimes it can result in refusal of some or all vaccines 
(56,57). Use of alternative vaccination schedules leads to under immunization and has been 
shown to increase significantly the risk of contracting and spreading vaccine-preventable 
disease (56).  
 
1.6.1. Anti-vaccination movements 
One potential obstacle to parents vaccination intention is the popularity of anti-vaccine 
conspiracy theories (58). 
In 1998, a paper in The Lancet described a small group of children experiencing 
developmental regression, including autism, and gastrointestinal problems (59). Andrew 
Wakefield’s article was responsible by raising a massive wave of concerns among parents 
toward MMR vaccine in many regions of the world (58). Wakefield’s association between MMR 
vaccine and two serious illnesses: inflammatory bowel disease and autism, led many parents 
to refuse this vaccine (59). A further article made additional claims that MMR vaccine was 
never properly tested (60). Although the majority of the authors of the original scientific paper 
linking MMR, autism and inflammatory bowel disease published a retraction of this 
interpretation and it has been proven that this study was false and that there was no scientific 
evidence to support the link between MMR and autism, MMR vaccination rates lie well below 
the recommended 95% uptake (53,58). Since then, parental concerns about perceived vaccine 
safety issues have led increasing numbers of parents to refuse or delay vaccination for their 
children, although the research has since been discredited and the author is no longer 
permitted to practice medicine (58,61,62) 
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In 1999, concerns were raised in the United States of America (USA) regarding exposure 
to mercury following immunization with thiomersal-containing vaccines (21). Three ecological 
studies suggesting an association between thiomersal and neurodevelopmental disorders 
were found to be fraught with methodological flaws (21). In addition, the continuous increase 
in the number of cases of autism diagnosed in the USA despite removal of thiomersal from 
most vaccines strongly argues against a causal association (21). Recently published studies 
confirm that in all populations studied, including pre-term and low birth-weight babies, the half-
life of ethylmercury in blood is between 3 and 7 days (21). The Global Advisory Committee on 
Vaccine Safety concluded that animal or human toxicity studies suggest that the levels of 
ethylmercury attained in the blood and brain from cumulative doses of vaccines do not reach 
toxic levels, making biologically implausible any relation between thiomersal in vaccines and 
neurological toxicity (21). 
Many other anti-vaccine conspiracy theories have emerged in recent years such as the 
belief that large pharmaceutical companies and governments are covering up information 
about vaccines to meet their own sinister objectives (58). According to the most popular 
theories, pharmaceutical companies stand to make such healthy profits from vaccines that 
they bribe researchers to fake their data cover up evidence of the harmful side effects of 
vaccines, and inflate statistic on vaccine efficacy (58). Anti-vaccine conspiracy theories 
therefore reflect suspicion and mistrust of scientific research examining vaccine efficacy and 
safety (58). Beliefs or exposure to conspiracy theories, negatively influence parent’s attitudes 
toward the dangers of vaccines and their subsequent decision to vaccinate their children (58). 
Parental perception of vaccine safety play an important role in parental decisions to 
vaccinate their children (58). Many parents believe that vaccines have dangerous side effects, 
and that exposure to the disease itself would often be preferable to the vaccination (58). 
Anti-vaccination ideals impact has exponentially grown on society due to current 
improvements on information sharing, the proliferation of vaccine information on the internet 
can both provide answers and raise concerns, and it can be difficult for parents to determine 
trustworthiness of online sources, such concerns could erode public confidence in vaccine 
safety (55). 
Anti-vaccination movements have been showing a significant impact on vaccination 
intentions. Jolley & Douglas research suggests that beliefs or exposure to anti-vaccine 
conspiracy theories are associated with reduced vaccination intentions and it may present an 
obstacle to vaccine uptake (58). 
In Portugal, it seems like there’s no records or publications of an organized anti-
vaccination movement like it happens in other European countries, as for example, 
Netherlands (63).  
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In the other hand, Netherlands has a well-known group of parents who refuse vaccination 
including Protestants living in what is called the Bible Belt region, which stretches from the 
southwest to the northeast of the country (64). The members of Reformed Congregations 
believe that vaccination is contrary to the providence of God (37). This group is at risk for 
epidemics as a result of socio-geographical clustering, which has been observed for polio, 
measles, mumps and rubella (37). Anthroposophics believe that experiencing some childhood 
diseases may contribute to strengthening body and mind (37). They are scattered throughout 
the Netherlands, but clustering in anthroposophic schools is present (37). In 2008, an outbreak 
occurred at several anthroposophical schools in the Netherlands and also in anthroposophical 
communities abroad (37). 
Besides this well-known group of anti-vaccination activists, in the last two decades, a 
broader anti-vaccination movement has emerged, including homeopaths and adherents of 
natural and alternative medicine (65). They question the self-evidence with which government 
provides and promotes large-scale vaccination programs. Some argue that diseases such as 
measles could provide someone with greater resilience against diseases like cancer and 
allergies later in life (65). Others emphasise the negative effects of vaccines, they argue 
vaccines contain dangerous toxic chemicals and overwhelm the immune system of young 
children (65).  
 The aim of this study is to analyse adverse events following immunisation cases in the 
Portuguese paediatric population between 2012 and 2016. Vaccine tendency in Portugal was 
analysed with resource to vaccine coverage variation and the number of vaccine-preventable 
disease cases in paediatrics in Portugal. These records were compared to The Netherlands 
data. An European country, with proximal population compared to Portugal (10 324 611 
population in Portugal, 17 018 408 population in The Netherlands 2016 (66)), where anti-
vaccination movements are well-known. 
The secondary outcome of this research will be achieved with a systematic review, 
being the objective to identify the reasons and factors behind parent’s decision to not 
vaccinate, delay or question one or more vaccines included in the National Immunization 
Program in high-income countries.  
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2. CHAPTER 2 – RETROSPECTIVE STUDY ON ADVERSE DRUG 
REACTION IN PAEDIATRICS TO DTPa AND MMR VACCINES IN 
PORTUGAL, FROM 2012 TO 2016 
2.1. Introduction 
According to European Medicines Agency’s (EMA) Guideline on good pharmacovigilance 
practices, Adverse drug reaction (ADR) is all noxious and unintended responses to a medicinal 
product,  a causal relationship between a medicine and an adverse event is at least a 
reasonable possibility (67). Adverse reactions may arise from the use of the product within or 
outside the terms of the marketing authorisation or from occupational exposure (67). 
Conditions outside the marketing authorization include off-label use, overdose, misuse, abuse 
and medication errors (67). According to DIRECTIVE 2001/83/EC, serious adverse reaction is 
defined as an adverse reaction which results in death, is life-threatening, requires in-patient 
hospitalisation or prolongation of existing hospitalisation, results in persistent or significant 
disability or incapacity, or is a congenital anomaly/ birth defect (68). 
ADR can be classified according to six different types (39,69). Type A (Augmented) 
reactions are dose-related, are predictable from the known pharmacology of a drug and are 
associated with high morbidity and low mortality (39,69). Type B (Bizarre) reactions are non-
dose-related, idiosyncratic, bizarre or novel responses that cannot be predicted from the 
known pharmacology of a drug and are associated with low morbidity and high mortality 
(39,69). Type C (continuing) are related to both dose and time are associated to the cumulative 
dose, type D (delayed use) are delayed reactions, occurs or becomes apparent time after the 
use of the drug, type E (end of use) reactions are related to withdrawal effects, type F (Failure) 
reactions are unexpected failure of therapy, often caused by drug interactions (39,69). 
An Adverse event following immunization (AEFI) is any untoward medical occurrence 
which follows immunization and which does not necessarily have a causal relationship with the 
usage of the vaccine (70). The adverse event may be any unfavourable or unintended sign, 
abnormal laboratory finding, symptom or disease (70). Serious AEFIs are those which are life-
threatening, result in hospitalization or a prolongation of hospitalization, result in persistent or 
significant disability, or where the outcome is a birth defect or death (70). AEFI are grouped 
into five categories which are: vaccine product-related reaction (caused or precipitated by a 
vaccine due to one or more of the inherent properties of the vaccine product) , vaccine quality 
defect-related reaction (one or more quality defects of the vaccine product including its 
administration device as provided by the manufacturer), immunization error-related reaction 
(inappropriate vaccine handling, prescribing or administration and thus its nature is 
preventable), immunization anxiety-related reaction (AEFI arising from anxiety about the 
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immunization) and coincidental event (caused by something other than the vaccine product, 
immunization error or immunization anxiety) (70).  
A ten-year study performed by Nogueira Guerra et al. showed that the most frequent 
ATC codes involved in suspected ADR, in a Portuguese paediatric population, were vaccines 
(n=842, 42%) and antibacterial for systemic use (n=336, 17%) (43).  
The most frequent adverse events following immunisation (AEFI) are mild cutaneous 
reactions in the local site of the injection, fever and crying (35,38). Drugs, including vaccines, 
have been determined to rarely cause anaphylaxis (42). The risk of anaphylaxis is less than 
two cases per million doses of vaccines administered to children and adolescents (42). 
Although it is serious and can be fatal, death and other complications can be prevented with 
rapid treatment using effective medications including epinephrine, corticosteroids and beta-
agonists (42). 
Healthcare providers can take specific actions to help prevent adverse reactions, 
including proper screening for contraindications and precautions, and observing a 15-minute 
waiting period after vaccination to prevent fall-related injuries from syncope (42). 
As vaccines are generally administered to healthy subjects, often young children, 
adverse reactions have a strong impact on the immunization acceptability as well as on its risk/ 
benefit balance assessment (71).   
2.2. Aims 
This study aimed to analyse a paediatric case series of ADR spontaneous reports to DTPa 
and MMR vaccines received by the Portuguese Pharmacovigilance System of the National 
Authority of Medicines and Health Products, (INFARMED, I.P.) between 2012 and 2016. 
2.3. Methods 
2.3.1. Data Source 
For this study, ADR reports received by the National Pharmacovigilance System from 
01.01.2012 to 31.12.2016 concerning individuals aged from birth to 18 years old exposed to 
diphtheria, tetanus and pertussis vaccine (DTPa), and/ or to measles, mumps and rubella 
vaccine (MMR) were requested to the INFARMED, I.P.  Other vaccine combinations which 
includes DTPa or MMR vaccines were included for analysis. If the subject was exposed to 
multiple vaccines/ drugs at the same period, there can be more than one suspected medicine 
of adverse reaction, this explains why we include other vaccines than the selected ones.  
The terminology used to code ADRs was based on the Medical Dictionary for Regulatory 
Activities (MedDRA). Medical terms are coded according to System Organ Classes (SOC) 
15 
 
affected. Where a single report included more than one adverse event classified under the 
same MedDRA SOC classification, these were treated as one adverse event. 
ADR were characterized as serious if it corresponds to “any untoward medical 
occurrence that at any dose results in death, is life-threatening, requires hospitalization or 
prolongation of existing hospitalization, results in persistent or significant disability or 
incapacity, or is a congenital anomaly/ birth defect, is a medically important event or reaction. 
Medical and scientific judgement should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardise the patient 
or may require intervention to prevent one of the other outcomes listed in the definition above”. 
The suspected drugs involved were presented as medicinal product’s name and 
characterized by therapeutic group according to the WHO Anatomical Therapeutic Chemical 
(ATC) classification system. 
A single report may have more than one suspected medicinal product. In each report, 
the number of ATC accounted corresponds to the number of different suspected medicinal 
products. In this study, we did not receive information on causality assessment of the adverse 
drug reaction to estimate the strength of relationship between drug(s) exposure and the 
occurrence of adverse reaction(s). 
2.3.2. Variables 
The variables analysed in this study were: 
▪ The number of adverse drug reaction notification by year of report; 
▪ Patients demographics regarding age and gender; 
▪ The source of notification, according to the region or entity (industry) from where it 
was reported, and the type of reporter (nurse, physician, pharmacist, 
pharmaceutical industry, patient); 
▪ ADR report according to its SOC, one single report may refer to multiple ADR so 
the number of ADRs may be higher than the number of reports shown in the 
overview; 
▪ MedDRA Preferred Term (MedDRA PT) of the reported adverse reactions for the 
most frequent SOC involved in the reports; 
▪ ADR seriousness, associated criteria (hospitalization, congenital anomaly, 
disability, life threatening, other) and outcome; 
▪ ATC codes of the suspected drugs of ADR reports.  
2.3.3. Statistical Analysis 
Descriptive statistical analysis was performed using SPSS ™ software. Relative and absolute 
frequencies were calculated. 
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2.4. Results 
2.4.1. Adverse drug reaction reports to DTPa and MMR in paediatric population 
From 2012 to 2016, a total of 591 ADR reports, concerning individuals in paediatric 
population (≤18 years old) exposed to diphtheria, tetanus and pertussis vaccine (DTPa), and/ 
or to measles, mumps and rubella vaccine (MMR), were received by the Portuguese 
Pharmacovigilance System. The 591 ADR reports analysed included a total of 1964 ADR, with 
an approximate average of 3,32 adverse reactions per report (figure 1). According to data, 
2013 corresponded to the year with more number of DTPa and MMR related ADR reports 
(n=181), in 2012 a lower number of ADR were reported (n=86). 
 
 
Figure 1. Number of adverse drug reactions (ADR) reports to diphtheria, tetanus and pertussis vaccine, and/ or to 
measles, mumps and rubella vaccine in paediatric population (≤18 years old) versus Portuguese number of births 
by year (estimated from birth rate according to Portuguese population) (72,73).  
 
In the same period, a total of 22571 ADR spontaneous reports were received by the 
INFARMED, concerning all medicines (figure 2). From 2012 to 2016 the total number of ADR 
reports, concerning all medicines, is increasing. DTPa and MMR vaccines adverse drug 
reaction reports in paediatrics is suffering a decrease from 2013 to 2016. It represents 1,56% 
(2016), to 5,23% (2013) of the total ADR cases received by the INFARMED. According to this 
study, ADR reports to DTPa and MMR in paediatrics represent 43,58% (n=181) in 2013 of the 
total reports received by the INFARMED concerning vaccines class (ATC – J07), to 26,03% 
(n=89) in 2016 (figure 3). 
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Figure 2. Number of adverse drug reaction notification to diphtheria, tetanus and pertussis vaccine, and/ or to 
measles, mumps and rubella vaccine in paediatric population (≤18 years old) versus total number of ADR 
notification reported to the National Pharmacovigilance System, from 2012 to 2016. 
 
 
Figure 3. Number of adverse drug reaction notification to diphtheria, tetanus and pertussis vaccine, and/ or to 
measles, mumps and rubella vaccine in paediatric population (≤18 years old) compared to the total number of 
adverse drug reaction notification received by the INFARMED for all vaccines (ATC – J07). 
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2.4.2. Adverse drug reaction reports distribution according to the region of origin 
According to this study, from the total of 591 ADR reports, 36,38% (n=215) were 
originated in the centre region, followed by Lisbon and Tagus Valley, 24,87% (n=147), and 
North, 22,34% (n=132). 1,35% (n=8) of the total ADR notification were directly reported by the 
industry (figure 4). 
 
 
Figure 4. Adverse drug reaction notification to diphtheria, tetanus and pertussis vaccine, and/ or to measles, mumps 
and rubella vaccine in paediatric population (≤18 years old) according to notification origin. 
 
2.4.3. Characterization of the affected patient  
Population demographics were studied, the most predominant age group of the ADR 
reports in this study was from 3 to 12 years-old (54,7%, n=323), followed by age group 2 
months to 3 years-old, (26,1%, n=154), 12 to 18 years-old (16,8%, n=99), 0 to 2 months (2,0%, 
n=12), in three the age was not described (table 1). The median age was 5 years old and the 
mode was 5 years old as well (standard deviation: 4,75 years). 57,5% of the total ADR reports 
occurred in male gender, and 42,1% in female, 2 ADR reports did not specify the gender of 
the individual. We found a male predominance throughout all age groups. 
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Table 1. Demographic information of the studied population. Individuals gender number and 
percentage distributed by age group. 
 
 Gender Total 
 
N (%) 
Unknown N (%) Female N (%) Male 
N (%) 
Age Group Unknown 0 (0%) 1 (33,3%) 2 (66,7%) 3 (0,5%) 
[0-2m[ 0 (0%) 5 (41,7%) 7 (58,3%) 12 (2,0%) 
[2m-3y[ 1 (0,6%) 75 (48,7%) 78 (50,6%) 154 (26,1%) 
[3y-12y[ 1 (0,3) 132 (40,9%) 190 (58,8%) 323 (54,7%) 
[12y-18y] 0 (0%) 36 (36,4%) 63 (63,6%) 99 (16,8%) 
Total 2 (0,3%) 249 (42,1%) 340 (57,5%) 591 (100%) 
 
 
 
 
Figure 5. Age group distribution of the total 591 adverse drug reaction (ADR) reports. 
  
2.4.4. Adverse drug reaction according to reporter profile 
From the total of 591 ADR reports, the majority of reports were submitted by nurses 
(n=355, 60,1%), followed by physicians (n=218, 36,9%), pharmacists (n=9, 1,5%), other 
sources (n=6, 1%) and patient/ non-healthcare professionals (n=3, 0,5%) (figure 6). ADR 
reports concerning all medicines reported to the National Pharmacovigilance System from 
2012 to 2016 shows a different distribution in terms of the type of reporter. In this case, the 
majority of reports were submitted by physicians, and the nurse occupies the third place in 
ADR reporting. 
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Figure 6. Adverse drug reaction reports to DTPa and MMR vaccines in the paediatric population versus the total of 
the adverse drug reaction reported to the National Pharmacovigilance System concerning all medicines in the same 
period (2012 to 2016), according to the type of reporter.  
 
2.4.5. ADR report System Organ Class 
The total 591 ADR reports analysed included a total of 1964 ADR, 21 different system 
organ class (SOC) were involved (table 2). In the same report, more than one reported reaction 
could correspond to the same SOC, in that case we just counted the corresponding SOC as 
one. The most frequently reported reactions were associated to general disorders and 
administration site conditions with 39,5% (n=475) of ADR, followed by injury, poisoning and 
procedural complications with 14,3% (n=172), infections and infestations 13,5% (n=162), 
gastrointestinal disorders 12,3% (n=148), skin and subcutaneous tissue disorders 8,1% 
(n=97). 
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Figure 7. System Organ Class involved in the studied ADR reports. 
 
 
The five most frequent SOC involved in the ADR reports were analysed in detail in table 
2. MedDRA Preferred Term (MedDRA PT) was accessed for each different SOC, and the 
frequency of the reported reaction. It is important to note, that in a single report it is possible 
to find more than one MedDRA PT corresponding to the same SOC. 
 
 
1
3
3
4
5
6
7
7
9
9
12
13
13
18
19
21
97
148
162
172
475
0 50 100 150 200 250 300 350 400 450 500
Reproductive system and breast disorders
Product issues
Renal and urinary disorders
Pregnancy, puerperium and perinatal…
Congenital, familial and genetic disorders
Metabolism and nutrition disorders
Blood and lymphatic system disorders
Eye disorders
Investigations
Psychiatric disorders
Vascular disorders
Cardiac disorders
Respiratory, thoracic and mediastinal…
Immune system disorders
Muscoskeletal and connective tissue…
Nervous system disorders
Skin and suncutaneous tissue disorders
Gastrointestinal disorders
Infections and infestations
Injury, poisoning and procedural…
General disorders and administration site…
Total number of SOC reported (N)
S
y
s
te
m
 O
rg
a
n
 C
la
s
s
 (
S
O
C
) 
in
v
o
lv
e
d
Sistem Organ Class (SOC) involved in ADR reports
22 
 
Table 2. Most frequent System Organ Class involved in the studied adverse drug reaction 
reports and its most frequent MedDRA Preferred Term.  
System Organ Class/ MedDRA Preferred Term 
 
Total Number of SOC reported (N) 
 
General disorders and administration site conditions 1093 
Pyrexia 139 
Vaccination site oedema 117 
Injection site erythema 100 
Vaccination site erythema 85 
Vaccination site warmth 66 
Vaccination site pain 48 
Drug ineffective 46 
Injection site oedema 41 
Vaccination site inflammation 41 
No adverse event 34 
Injury, poisoning and procedural complications 191 
Vaccination failure 131 
Vaccination error 20 
Medication error 18 
Drug administration error 6 
Expired product administered 4 
Inappropriate schedule of drug administration 4 
Drug administered to patient of inappropriate age 2 
Incorrect product storage 1 
Incorrect route of drug administration 1 
Wrong drug administered 1 
Infections and infestations 171 
Mumps 67 
Pertussis 54 
Vaccination site cellulitis 18 
Cellulitis 7 
Orchitis 4 
Exanthema subitum 3 
Parotitis 3 
Vaccination site abscess 2 
Viral infection 1 
Viral parotitis 1 
Gastrointestinal disorders 162 
Parotid gland enlargement 123 
Vomiting 10 
Diarrhoea 6 
Abdominal pain 5 
Nausea 3 
Salivary hypersecretion 2 
Oral disorder 1 
Oral mucosal eruption 1 
Post-tussive vomiting 1 
Rectal prolapse 1 
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Skin and subcutaneous tissue disorders 152 
Erythema 45 
Rash 19 
Pruritus 17 
Rash generalised 14 
Oedema 8 
Rash macular 8 
Generalised erythema 5 
Rash papular 5 
Rash pruritic 3 
Skin warm 3 
 
General disorders and administration site condition corresponds to 55,65% (n=1093) 
of the total 1964 reported MedDRA PT. In this particular case, we just analysed the most 
frequent MedDRA PT corresponding to this SOC. The most reported MedDRA PT in this SOC 
was pyrexia with 7,08% (n=139) of the total 1964 reported MedDRA PT, followed by 
vaccination site oedema (5,96%, n=117), injection site erythema (5,09%, n=100), vaccination 
site erythema (4,33%, 85) and vaccination site warmth (3,36%, 66). 
System organ class injury, poisoning and procedural complications, accounts for 9,73% 
(n=191) of the total 1964 reported MedDRA PT. The most frequent cited MedDRA PT in this 
SOC are vaccination failure (6,67%, n=131), vaccination error (1,02%, n=20), medication error 
(0,92%, n=18), drug administration error (0,31%, n=6) and inappropriate schedule of drug 
administration (0,20%, n=4). 
Infection and infestation SOC is present in 8,71% (n=171) of the total 1964 reported 
MedDRA PT. The most reported MedDRA PT in this SOC are mumps (3,41%, n=67), pertussis 
(2,75%, n=54), vaccination site cellulitis (0,92%, n=18), cellulitis (0,36%, n=7), orchitis (0,20%, 
n=4). 
Gastrointestinal disorder SOC occurs in 8,25% (n=162) of the total 1964 reported 
MedDRA PT. Parotid gland enlargement (6,26%, n=123) is the most cited MedDRA PT in this 
SOC, followed by vomiting (0,51%, n=10), diarrhoea (0,31%, n=6), abdominal pain (0,25%, 
n=5) and nausea (0,15%, n=3). 
The fifth most frequent system organ class present in the analysed ADR reports was 
skin and subcutaneous tissue disorders, it accounts for 7,74% (n=152) of the total 1964 
reported MedDRA PT. The most frequent MedDRA PT in this SOC are erythema (2,29%, 
n=45), rash (0,97%, n=19), pruritus (0,87%, n=17), rash generalised (0,71%, n=14) and rash 
macular (0,41%, n=8). 
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Table 3. System Organ Class (SOC) involved in ADR reports studied per age group. 
 
 
System Organ Class (SOC) involved (N) Age Group Total 
N, (%) 
[0-2m[ 
N (%) 
[2m-3y[ 
N (%) 
[3y-12y[ 
N (%) 
[12y-18y] 
N (%) 
Unknown 
N (%) 
General disorders and administration site conditions 5 (0,42%) 110 (9,14%) 284 (23,59%) 73 (6,06%) 3 (0,25%) 475 (39,5%) 
Injury, poisoning and procedural complications 4 (0,33%) 31 (2,57%) 45 (3,74%) 92 (7,64%) 0 (0,00%) 172 (14,3%) 
Infections and infestations 3 (0,25%) 31 (2,57%) 67 (5,56%) 61 (5,07%) 0 (0,00%) 162 (13,5%) 
Gastrointestinal disorders 2 (0,17%) 19 (1,58%) 37 (3,07%) 90 (7,48%) 0 (0,00%) 148 (12,3%) 
Skin and subcutaneous tissue disorders 1 (0,08%) 32 (2,66%) 64 (5,32%) 0 (0,00%) 0 (0,00%) 97 (8,1%) 
Nervous system disorders 0 (0,00%) 12 (1,00%) 8 (0,66%) 1 (0,08%) 0 (0,00%) 21 (1,7%) 
Musculoskeletal and connective tissue disorders 1 (0,08%) 3 (0,25%) 15 (1,25%) 0 (0,00%) 0 (0,00%) 19 (1,6%) 
Immune system disorders 0 (0,00%) 8 (0,66%) 10 (0,83%) 0 (0,00%) 0 (0,00%) 18 (1,5%) 
Cardiac disorders 2 (0,17%) 6 (0,50%) 5 (0,42%) 0 (0,00%) 0 (0,00%) 13 (1.1%) 
Respiratory, thoracic and mediastinal disorders 3 (0,25%) 10 (0,83%) 0 (0,00%) 0 (0,00%) 0 (0,00%) 13 (1.1%) 
Vascular disorders 0 (0,00%) 4 (0,33%) 8 (0,66%) 0 (0,00%) 0 (0,00%) 12 (1,0%) 
Investigations 2 (0,17%) 3 (0,25%) 4 (0,33%) 0 (0,00%) 0 (0,00%) 9 (0,7%) 
Psychiatric disorders 0 (0,00%) 7 (0,58%) 2 (0,17%) 0 (0,00%) 0 (0,00%) 9 (0,7%) 
Blood and lymphatic system disorders 0 (0,00%) 4 (0,33%) 3 (0,25%) 0 (0,00%) 0 (0,00%) 7 (0,6%) 
Eye disorders 0 (0,00%) 4 (0,33%) 3 (0,25%) 0 (0,00%) 0 (0,00%) 7 (0,6%) 
Metabolism and nutrition disorders 1 (0,08%) 3 (0,25%) 2 (0,17%) 0 (0,00%) 0 (0,00%) 6 (0,5%) 
Congenital, familial and genetic disorders 2 (0,17%) 2 (0,17%) 0 (0,00%) 1 (0,08%) 0 (0,00%) 5 (0,4%) 
Pregnancy, puerperium and perinatal condition 1 (0,08%) 1 (0,08%) 0 (0,00) 2 (0,17%) 0 (0,00%) 4 (0,3%) 
Product issues 0 (0,00%) 3 (0,25%) 0 (0,00%) 0 (0,00%) 0 (0,00%) 3 (0,2%) 
Renal and urinary disorders 0 (0,00%) 2 (0,17%) 0 (0,00%) 1 (0,08%) 0 (0,00%) 3 (0,2%) 
Reproductive system and breast disorders 0 (0,00%) 0 (0,00%) 1 (0,08%) 0 (0,00%) 0 (0,00%) 1 (0,1%) 
Total  
(N,%) 
27 
(2,24%) 
295  
(24,50%) 
558  
(46,35%) 
321  
(26,66%) 
3 
(0,25%) 
1204  
(100,00%) 
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2.4.6. Adverse drug reaction seriousness 
ADR reports were classified according to its seriousness (figure 8), from the total 591 
ADR notifications, 55,33% (n=327) were considered serious. 43,73% (n=143) of serious ADR 
reports occurred in age group [3y-12y[. In age group [12y-18y], the total number of ADR 
reported (n=99, 30,28%) were considered serious. 
Among the 327 serious ADR report, 13,46% (n=44) required patient hospitalization, 22 
cases (50,00%) occurred in [3y-12y[ age group, 7,34% (n=24) represented temporary or 
definitive disability, 2,14% (n=7) were considered life threatening, with  4 cases (57,14%) in 
[2m-3y[ age group (figure 9). 64,53% (n=211) of patients that reported a serious ADR 
completely recovered, 1,22% (n=4) were classified as persistent without recovery, 8,87% 
(n=29) remain in recovery process, and there are 25,38% (n=83) cases with unknown records 
(figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Adverse Drug Reaction (ADR) seriousness by age group. 
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Figure 9. Serious Adverse Drug Reaction (ADR) report seriousness criteria by age group. The criteria “Other” 
represents ADR that are not included in the existing criteria due to its specificity, but it is considered medical 
important and usually requires medical intervention. 
 
 
Figure 10. Total Adverse Drug Reaction (ADR) outcome versus serious ADR outcome. 
 
2.4.7. Anatomical therapeutic chemical codes involved 
Although this study focusses on adverse drug reactions to diphtheria, tetanus and 
pertussis vaccine, and measles, mumps and rubella vaccine, other drugs or vaccines may be 
involved in the ADR. From the 591 ADR reports, 20 different Anatomical Therapeutic Chemical 
1 2 3 0 02
19
50
3 40
22
98
20
30 1
98
0 00 0 0 1 0
0
20
40
60
80
100
120
Congenital
Anomally
Hospitalization Other Incapacity
(temporary or
definitive)
Life threatening
N
u
m
b
e
r 
o
f 
S
e
ri
o
u
s
 A
D
R
 r
e
p
o
rt
Severity criteria
Serious ADR report seriousness criteria
[0-2m[
[2m-3y[
[3y-12y[
[12y-18y]
Unknown
420
119
45
7
211
83
29
4
0
50
100
150
200
250
300
350
400
450
Recovered Unknown In recovery Persistent
without
recovery
N
u
m
b
e
r 
o
f 
A
D
R
 r
e
p
o
rt
ADR outcome
ADR outcome
ADR Total
ADR serious
27 
 
(ATC) codes were involved in suspected ADR (table 4). One report may present more than 
one suspected drug of adverse reaction, so ADR reports included a total of 761 ATC codes. 
We analysed ATC codes involved in suspected ADR in each age group. The most 
representative ATC code was J07CA02 diphtheria-pertussis-poliomyelitis-tetanus (35,48%, 
n=270), followed by J07BD52 measles, combinations with mumps and rubella, live attenuated 
(28,65%, n=218), J07AX Other bacterial vaccines (13,14%, n=100), J07CA06 diphtheria-
haemophilus influenzae B-pertussis-poliomyelitis-tetanus (13,01%, n=99) and J07BC01 
hepatitis B, purified antigen (2,63%, n=20). In age group [0-2m[ the most frequent ATC code 
was J07CA06 diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus (0,79%, 
n=6), in age group [2m-3y[ was J07AX Other bacterial vaccines (8,15%, n=62) followed by 
J07CA06 diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus (6,96%, n=53), 
in age group [3y-12y[ was J07CA02 diphtheria-pertussis-poliomyelitis-tetanus (33,64%, 
n=256) and in age group [12y-18y] was J07BD52 measles, combinations with mumps and 
rubella, live attenuated (13,53%, n=103) (figure11). 
 
 
Figure 11. Five most representative Anatomical Therapeutic Chemical (ATC) codes per age group. 
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2.4.8. Suspected medicinal product’s name of ADR report 
Suspected drugs involved in ADR reports were analysed, although our study focus on 
diphtheria, tetanus and pertussis vaccine, and measles, mumps and rubella vaccine, if the 
subject was exposed to multiple drugs, it can originate more than one suspected drug of 
causing the reported adverse reaction, other than the selected ones. A total of 761 drugs were 
reported as suspected drug of adverse reaction (table 5). 28 different drugs were involved and 
7 drugs were not specified.  
The most frequent drug in ADR report was INFANRIX TETRA® vaccine (n=200, 
24,8%), followed by M-M-RVAXPRO® vaccine (n=100, 12,5%), INFANRIX HIB (n=93, 11,6%), 
M-M-R® II vaccine (n=93, 11,6%), PENTAVAC® vaccine (n=78, 9,00%) (figure 12). 
Our data lacks causality assessment of the adverse drug reaction to estimate the 
strength of relationship between drug(s) exposure and occurrence of adverse reaction(s). 
 
 
Figure 12. Most frequent suspected drugs of adverse drug reaction reported.  
 
INFANRIX TETRA® Diphtheria, tetanus, pertussis and poliomyelitis vaccine  
M-M-RVAXPRO® Measles, mumps and rubella vaccine 
INFANRIX HIB Diphtheria, tetanus, pertussis and haemophilus type b vaccine 
M-M-R® II Measles, mumps and rubella vaccine 
PENTAVAC Diphtheria, tetanus, pertussis, poliomyelitis and haemophilus type b vaccine 
TETRAVAC® Diphtheria, tetanus, pertussis and poliomyelitis vaccine 
Engerix B® Hepatitis B vaccine  
INFANRIX®-IPV+Hib Diphtheria, tetanus, pertussis, poliomyelitis and haemophilus type b vaccine 
Menjugate Kit® Meningococcal vaccine 
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Table 4. ATC codes involved in suspected ADR per age group. 
 
 
ATC Classification (N) Age Group Total  
 N (%) [0-2m[ 
N (%) 
[2m-3y[ 
N (%) 
[3y-12y[ 
N (%) 
[12y-18y] 
N (%) 
Unknown  
N (%) 
G02CB03 Cabergoline 1 (0,13%) 0 (0,00%) 0 (0,00%) 0 (0,00%) 0 (0,00%) 1 (0,13%) 
J07A Bacterial Vaccines 0 (0,00%) 0 (0,00%) 1 (0,13%) 2 (0,26%) 0 (0,00%) 3 (0,39%) 
J07AG Haemophilus influenzae B vaccines 0 (0,00%) 0 (0,00%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 1 (0,13%) 
J07AH Meningococcal vaccines 1 (0,13%) 12 (1,58%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 14 (1,84%) 
J07AH07 meningococcus C, purified polysaccharides 
antigen conjugated 
0 (0,00%) 1 (0,13%) 0 (0,00%) 0 (0,00%) 0 (0,00%) 1 (0,13%) 
J07AH09 meningococcus B, multicomponent vaccine 0 (0,00%) 1 (0,13%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 2 (0,26%) 
J07AL02 pneumococcus, purified polysaccharides 
antigen conjugated 
2 (0,26%) 11 (1,45%) 1 (0,13%) 1 (0,13%) 0 (0,00%) 15 (1,97%) 
J07AM51 tetanus toxoid, combinations with diphtheria 
toxoid 
2 (0,26%) 1 (0,13%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 4 (0,53%) 
J07AX other bacterial vaccines 1 (0,13%) 62 (8,15%) 36 (4,73%) 1 (0,13%) 0 (0,00%) 100 (13,14%) 
J07BC01 hepatitis B, purified antigen 1 (0,13%) 17 (2,23%) 1 (0,13%) 1 (0,13%) 0 (0,00%) 20 (2,63%) 
J07BD52 measles, combinations with mumps and 
rubella, live attenuated 
5 (0,66%) 34 (4,47%) 75 (9,86%) 103 (13,53%) 1 (0,13%) 218 (28,65%) 
J07BD54 measles, combinations with mumps, rubella 
and varicella, live attenuated 
0 (0,00%) 0 (0,00%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 1 (0,13%) 
J07BF03 poliomyelitis, trivalent, inactivated, whole 
virus 
0 (0,00%) 1 (0,13%) 1 (0,13%) 1 (0,13%) 0 (0,00%) 3 (0,39%) 
J07BH01 rota virus, live attenuated 0 (0,00%) 2 (0,26%) 0 (0,00%) 0 (0,00%) 0 (0,00%) 2 (0,26%) 
J07BH02 rota virus, pentavalent, live, reasserted 0 (0,00%) 2 (0,26%) 1 (0,13%) 0 (0,00%) 0 (0,00%) 3 (0,39%) 
J07BM01 papillomavirus (human types 6, 11, 16, 18) 0 (0,00%) 1 (0,13%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 2 (0,26%) 
J07CA02 diphtheria-pertussis-poliomyelitis-tetanus 0 (0,00%) 8 (1,05%) 256 (33,64%) 4 (0,53%) 2 (0,26%) 270 (35,48%) 
J07CA05 diphtheria-hepatitis B-pertussis-tetanus 0 (0,00%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 0 (0,00%) 1 (0,13%) 
J07CA06 diphtheria-haemophilus influenzae B-
pertussis-poliomyelitis-tetanus 
6 (0,79%) 53 (6,96%) 39 (5,12%) 1 (0,13%) 0 (0,00%) 99 (13,01%) 
N02BE01 paracetamol 0 (0,00%) 0 (0,00%) 1 (0,13%) 0 (0,00%) 0 (0,00%) 1 (0,13%) 
Total 
N (%) 
19 
(2,50%) 
206  
(27,07%) 
413  
(54,27%) 
120  
(15,77%) 
3  
(0,39%) 
761  
(100%) 
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Table 5. Absolute and relative frequency of the suspected drugs of adverse drug reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5. Discussion 
In the present study, from 2012 to 2016 a total of 591 ADR reports, concerning paediatric 
individuals exposed to DTPa, and/ or to MMR vaccines, were analysed. These results are 
substantially lower when compared with ADR reporting in The Netherlands. In Portugal, the 
rate of ADR reports concerning this vaccines in 2015 was 4,5 reports per 100 000 paediatric 
individuals, in The Netherlands it was 28,9 reports per 100 000 paediatric individuals. 
According to Herdeiro et al., the main limitation of the Portuguese spontaneous drug 
notification system is ADR under-reporting, it is estimated that only 6% of the total adverse 
drug reaction are notified (40). The highest proportion of reported ADR occurred in 2013 
(n=181), and the lowest proportion occurred in 2012 (n=86).  
DRUG NAME TOTAL (N) TOTAL (%) 
INFANRIX TETRA® 200 24,8 
M-M-RVAXPRO® 100 12,5 
INFANRIX HIB 93 11,6 
M-M-R® II 93 11,6 
PENTAVAC® 78 9 
TETRAVAC® 67 8,3 
ENGERIX B® 18 2 
UNKNOWN MMR VACCINE 17 2,1 
INFANRIX®-IPV+HIB 14 1,7 
MENJUGATE KIT® 14 1,7 
PREVENAR 13® 14 1,6 
TRIVIRATEN BERNA 9 1,1 
INFANRIX® 7 0,9 
PENTAXIM® 6 0,6 
ROTATEQ® 3 0,2 
UNKNOWN DTAP-IPV VACCINE 3 0,4 
BEXSERO® 2 0,1 
BOOSTRIX® 2 0,2 
DT VAX ADULTO® 2 0,2 
DITANRIX® 2 0,2 
GARDASIL® 2 0,2 
POLIOVACCINE SSI 2 0,2 
ROTARIX® 2 0,1 
UNKNOWN HEPATITIS B VACCINE  2 0,2 
DOSTINEX 1 0,1 
IMOVAX® POLIO  1 0,1 
INFANRIX PENTA® 1 0,1 
MENINGITEC® 1 0,1 
PANASORBE 1 0,1 
PREVENAR® 1 0,1 
TETRACT-HIB® 1 0,1 
UNKNOWN DTPA VACCINE 1 0,1 
UNKNOWN DTAP/IPV/HIB VACCINE 1 0,1 
TOTAL  N (%) 761 100 
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According to INFARMED records, the number of adverse drug reaction reports regarding 
all medicines, is slightly increasing over the years from 3104 reports in 2012 to 5698 reports 
in 2016, this result may be explained by the increasing awareness of reporters and 
pharmacovigilance system work progress over the years. Adverse reaction following 
immunization is decreasing over the years, this may be linked with the Portuguese paediatric 
population decrease over the same period. Vaccines (ATC: J07) represent 6% to 12% of the 
total ADR reported to INFARMED between 2012 to 2016, it is one of the most representative 
ATC codes nationally notified. Adverse drug reaction to DTPa and MMR vaccines in 
paediatrics occupies between 26,03% (2016) and 43,58% (2013) of the total reported ADR to 
vaccines (ATC: J07). 
During this five-year period, the North region of Portugal has reported the highest number 
of adverse drug reaction, concerning all medicines, to the National Pharmacovigilance System. 
On the contrary, in this study, the highest proportion of ADR reports were notified by the Centre 
region (n=215) and the North region occupies the third place (n=132). 
The highest number of ADR, related to these vaccines were directly reported by nurses, if 
we compare this data to the overall ADR reports received by the INFARMED in the same 
period, we can realise that the highest frequency of ADR notification was done by the 
physician, followed by the pharmacist, and nurse occupies the third place in ADR reporting. 
The important role of nurse in reporting suspected ADRs in paediatrics has been verified in 
other studies. Hawcutt et al. conducted a study in the UK and concluded that nurse reports 
more suspected ADRs in children than any other health professional (74). This findings, 
however differ from The Netherlands case, where the patient is the first ADR reporter, followed 
by physician, pharmacist and general practitioners (75). In a study conducted in the 
Netherlands, the main reasons for patient to report ADR were to share their experiences, the 
severity of the reaction, worries about their own situation and the fact the ADR was not 
mentioned in the patient information leaflet (76). 
Nurses are the healthcare professional responsible by vaccine administration in healthcare 
institutions, this may explain their important role in the process of AEFI spontaneous reporting 
in paediatrics. 
The age group affected more prevalent among DTPa and MMR ADR reports was from 3 
years (inclusive) to 12 years (exclusive), a male predominance was found. This findings are in 
accordance with other AEFI studies concerning paediatric population (77). 
The system organ class most frequently involved in ADR reports was general disorders 
and administration site conditions. Pyrexia and vaccination site reactions such as oedema, 
erythema, warmth and pain were the most frequently reported adverse reactions. These 
results are in accordance with other studies. In a study conducted by Lareb, in 2015 in The 
Netherlands the most cited adverse event following immunisation was injection site reaction 
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(78), a study conducted in Denmark reported pyrexia and injection-site reactions as the most 
frequently reported AEFI following paediatric immunization (79), another study in Czech 
Republic reported local (redness, swelling, pain) as the most frequent AEFI (77).  
The system organ class injury, poisoning and procedural complications was the second 
most significant in terms of ADR reporting, since in the field of immunization, vaccine failure 
and lack of efficacy is considered an adverse drug reaction. 
From the total ADR reported in this study, 55,33% adverse reactions were considered 
serious. According to INFARMED data on ADR concerning all medicines in Portugal, between 
2012 and 2016 a total of 19952 ADR was reported, from those 14850 (74,43%) reports were 
classified as serious. These results may be linked to the special awareness of the 
pharmaceutical industry and healthcare professionals to report serious events in Portugal. In 
the older age group (12 years old to 18 years old), only serious adverse drug reaction was 
reported. 
The most frequent drugs suspected of ADR report in this study were INFARIX TETRA® 
against diphtheria, tetanus, pertussis and poliomyelitis and M-M-RVAXPRO® against 
measles, mumps and rubella. In march 2014, the batch number AC20B268AB of INFARIX 
TETRA® was suspended due to AEFI notifications reporting limb cellulitis, redness and fever 
(80).  
It is important to note that, in this study, other drugs than vaccines were classified as 
suspected drugs of causing the adverse drug reaction (as for example: Panasorbe®). This 
happens when more than one drug or vaccines are administered to the same subject in a 
similar temporal window, and we cannot exclude any of these medicines as suspected drug of 
adverse reaction without an appropriate causality assessment.  
 In this study, 71,06% of patients that reported an ADR completely recovered, still a vast 
percentage of the study population (20,13%) ADR outcome is unknown, in some cases 
healthcare professionals are unable to follow patient case evolution. 
2.5.1. Limitations 
The main limitation of this study is the absence of causality assessment of adverse drug 
reaction to the suspected vaccine, which we did not get assess to. This study may be 
susceptible to population selection bias, since in Portugal reports of serious ADR are specially 
encouraged. 
ADR under-reporting constitutes a limitation to this study, the spontaneous reports received 
illustrates just part of a wider reality.  
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3. CHAPTER 3 – ANALYSIS OF VACCINE COVERAGE AND VACCINE 
PREVENTABLE DISEASE CASES IN PORTUGAL AND IN THE 
NETHERLANDS 
3.1. Introduction 
The Portuguese National Immunization Program is available to every citizen present in 
Portugal, including legal and illegal immigrants (35). There are different vaccination schemes 
according to individual age, vaccine status, risk groups and other special circumstances (35). 
The recommended vaccine schedule objective is to achieve the best protection in the most 
adequate age and earlier as possible, because it is in the first year of age that children are 
most vulnerable to infectious diseases (35). Immunization should be scrupulously fulfilled at 
the recommended age without any delay to avoid disease complications which can be fatal 
(35).  
The immunisation coverage for the different vaccination included in the Netherlands’ NIP 
was with 92% to 99% high in report year 2016 (38). However, participation for most 
vaccinations declined by about 0,5% (38). For new-borns, this decline was observed for the 
second consecutive year (38). Such fluctuations were observed previously at regional level, 
but they are now, for the first time being observed nationwide (38). 
This raises a huge concern over the future of NIP, if vaccine coverage continues to decrease 
we will not be able to maintain herd immunity and consequently population will be susceptible 
to vaccine-preventable diseases. 
3.2. Aims 
The outcome of this study is to analyse vaccine coverage variation and the number of 
vaccine-preventable disease cases in paediatrics in Portugal and in The Netherlands, where 
anti-vaccination movements are well-known. 
3.3. Methods 
3.3.1. Data Sources 
For this study, NIP vaccine coverage data was collected from 2012 to 2016. Vaccine 
coverage was assessed at the age of 2 years old. So, we analysed vaccine coverage per 
vaccine, for age cohorts of newborns from 2010 to 2014.  
Portuguese vaccine coverage data was extracted from 2012 to 2016 for cohorts 2010 to 
2014 from the temporal series results of the evaluation of NIP, available on Directorate-
General of Health (DGS) website (81). MMR vaccine data from 2012 for cohort 2010 was 
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extracted from vaccination bulletin n.er 6, available on DGS website, data from 2013 for cohort 
2011 was extracted from vaccination bulletin n.er 7, available on DGS website, data from 2014 
to 2016 for cohorts 2012 to 2014 was extracted from the temporal series results of the 
evaluation of NIP, available on DGS website (81–83). 
 Vaccine coverage data from The Netherlands NIP, from 2012 to 2016 for cohorts 2010 to 
2014 was extracted from Netherlands’ National Vaccination Programme 2016 report (84).  
Vaccine preventable disease cases, for diseases included in the NIP, were analysed for 
Portugal and The Netherlands, from 2010 to 2016, in some cases data was not available for 
this period. Data was extracted from Surveillance Atlas of Infectious Diseases available on the 
European Centre for Disease Prevention and Control (ECDC) website. 
3.3.2. Variables 
The variables analysed were vaccine coverage percentage (%) per vaccine included in the 
NIP, per age cohort of newborns (2 years old).  
Vaccine preventable disease cases were analysed. We studied the reported number of 
cases per vaccine preventable disease included in the NIP per year, notification rate (number 
of cases per 100 000 population), age group (percentage of childhood cases, from birth to 14 
years old) and gender of the notified case, when available, we also included the number of 
deaths caused by the disease. 
3.3.3. Analysis 
A descriptive analysis was preformed to compare vaccine coverage data from Portugal to 
The Netherlands, we constructed bar graphs to analyse data. 
Narrative analysis was used as well, to examine vaccine preventable disease cases data 
extracted from Portugal and from The Netherlands.  
3.4. Results 
3.4.1. Vaccine coverage evolution in Portugal and in The Netherlands 
Vaccine coverage data was analysed for age cohorts of newborns (2 years old) 2010 to 
2014 corresponding to the reporting year 2012 to 2016. Figure 24, represents the percentage 
of individuals, per age cohort per vaccine, who fulfilled for each vaccine the recommended 
vaccination plan, for Portugal and for the Netherlands (81–84). 
In Portugal, the immunisation coverage (participation) on vaccines included in the NIP is 
considered a case of success with 96,1% to 99,1%, it is above WHO recommendations of 95% 
vaccination coverage. Vaccine coverage analysis shows slight variations over the selected age 
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cohorts. DTPa vaccine coverage suffered minor variations over the years, although, it 
continuously assured a minimum 96% vaccine coverage, in cohort 2010, vaccine coverage 
was 96,4% and in cohort 2014 it was 96,1% (figure 14). MMR vaccine coverage slightly 
changed from 98,0% to 97,9% (figure 15). Hib vaccine coverage increased from 96,3% in 
cohort 2010 to 98,7% in cohort 2014 (figure 16). BCG vaccine coverage ranges from 98,9% to 
97,5% (figure 13), HBV from 98,5% to 98,3% (figure 18) and MenC from 98,5% to 97,3% 
(figure 17).  
In the Netherlands vaccine coverage is considered high although in some cohorts it does 
not match with the 95% vaccine coverage recommendations of WHO. HBV vaccine coverage 
has increased over the studied cohorts with 19,7% for cohort 2010 to 93,1% for cohort 2014, 
although it does not comply with the 95% coverage, it suffered a great increase over the 
cohorts. In contrast, for the other vaccines we are experiencing vaccine coverage decline over 
the age cohorts, DTPa with 95,5% to 93,5% (figure 14), MMR with 96,1% to 93,8% (figure 15), 
Hib with 96,1% to 94,2% (figure 16) and MenC with 96,0% to 93,5% (figure 17). 
 
 
Figure 13. Vaccine coverage for birth cohorts of newborns (2 years old) 2010 to 2013, for Bacillus Calmette-Guérin 
(BCG) vaccine in Portugal (81). 
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Figure 14. Diphtheria, tetanus and acellular pertussis (DTPa) vaccine coverage for birth cohorts of newborns (2 
years old) from 2010 to 2013 in Portugal and in the Netherlands (81,84). 
 
Figure 15. Measles, mumps and rubella (MMR) vaccine coverage for birth cohorts of newborns (2 years old) from 
2010 to 2013 in Portugal and in the Netherlands (81–84). 
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Figure 16. Haemophilus Influenzae type b (Hib) vaccine coverage for birth cohorts of newborns (2 years old) from 
2010 to 2013 in Portugal and in the Netherlands (81,84). 
 
 
Figure 17. meningococcal C (MenC) vaccine coverage for birth cohorts of newborns (2 years old) from 2010 to 
2013 in Portugal and in the Netherlands (81,84). 
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Figure 18. Hepatitis B (HBV) vaccine coverage for birth cohorts of newborns (2 years old) from 2010 to 2013 in 
Portugal and in the Netherlands (81,84). 
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Figure 19. Vaccine coverage for birth cohorts of newborns (2 years old) 2010 to 2013 in Portugal and in The Netherlands regarding NIP vaccines against Hepatitis B (HBV), 
Diphtheria, tetanus and acellular pertussis (DTPa), Haemophilus Influenzae type b (Hib), meningococcal C (MenC), Measles, mumps and rubella (MMR) (81–84).
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3.4.2. Vaccine preventable disease cases analysis  
Vaccine preventable disease reported number cases and notification rate per 100 000 
population were analysed in Portugal and in the Netherlands for the period 2010 to 2016 
(measles and rubella). In case of hepatitis B and diphtheria, the period available for 
consultation was from 2010 to 2014. For tetanus, pertussis, invasive H. influenzae serotype B, 
mumps and tuberculosis it was possible to extract information from 2010 to 2015 (table 6). 
Data was extracted from ECDC Surveillance Atlas of Infectious Diseases. Note that we are 
analysing the number of reported cases, since we lack disease case confirmation, the number 
of reported cases can be higher than the real number of disease cases. 
In Portugal, the overall notification rate of vaccine preventable disease reported cases is 
considered low when compared with the European notification rate.  
3.4.2.1. Hepatitis B 
The number of hepatitis B reported cases in Portugal suffered a slight increase from 0 
cases in 2010 to 19 cases in 2014, which represents a notification rate increase from 0 to 0,18 
cases per 100 000 population. From 2010 to 2014, 34 cases of hepatitis B were reported, only 
1 case occurred in paediatric age (0-4 years), 69% cases occurred in male gender and 31% 
cases in female gender (figure 20). Although in the Netherlands the number of hepatitis B 
reported cases are decreasing, the numbers are still very high when compared to Portugal, 
ranging from 196 reported cases in 2010 to 142 in 2014 (1,18/ 100 000 population in 2010 to 
0,84/ 100 000 in 2014). From the total of 813 hepatitis B reported cases, 9 cases occurred in 
paediatric age (1 case – 0-4 years; 8 cases – 5-14 years), 77% cases occurred in male, 23% 
cases in female (table 6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Hepatitis B reported number cases per year from 2010 to 2014 in Portugal and in the Netherlands. 
 
41 
 
3.4.2.2. Tetanus 
Tetanus reported number cases in Portugal has maintained very low levels, resulting in 
small variations over the analysed period of time, with 3 reported cases in 2010 to 1 reported 
cases in 2015 (0,03/ 100 000 population in 2010 to 0,01/ 100 000 in 2015). During this 5 years, 
10 cases of tetanus were reported, resulting in 2 deaths, none of the reported cases occurred 
in paediatric age, and 20,00% reported cases occurred in male, 80,00% in female (figure 21). 
In the Netherlands notification rate is close to the Portuguese, although in 2011 there were 6 
reported cases (0,04/ 100 000 population), in 2010 and in 2015 only one case of tetanus was 
reported (0,01/ 100 000 in 2010 and in 2015). From 2010 to 2015 there were 11 cases of 
tetanus, resulting in one death in 2011, none of the reported cases occurred in paediatric age, 
and 73,00% cases occurred in male, 27,00% in female (table 6).  
 
Figure 21. Tetanus reported number cases per year from 2010 to 2015 in Portugal and in the Netherlands. 
 
3.4.2.3. Pertussis 
A notable increase in the notification rate of pertussis was observed in Portugal, 14 
reported cases in 2010 to 238 reported cases in 2015 (0,13/ 100 000 population in 2010 to 
2,29/ 100 000 in 2015). From 2010 to 2015 there were 701 reported cases of pertussis, 
resulting in a total of 8 deaths, 649 notified cases occurred in paediatric age (604 cases – 0-4 
years, 45 cases – 5-14 years), 48% cases occurred in male, 52% cases were from female. 
The Netherlands suffered an outstanding increase in the notification rate of pertussis from 
22,52 cases per 100 000 population in 2010 (3733 reported number cases) to 36,55 cases per 
100 000 population in 2015 (6178 reported number cases) with a total of 39260 reported cases 
from 2010 to 2015, which resulted in 6 deaths. 14229 cases occurred in paediatric age (2192 
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cases – 0-4 years, 12037 cases – 5-14 years), 44% of cases occurred in male, 56% cases in 
female (figure 22). 
 
Figure 22. Pertussis reported number cases per year from 2010 to 2015 in Portugal and in the Netherlands. Primary 
axis: Portugal’s reported cases number; secondary axis: The Netherlands’ reported cases number. 
 
3.4.2.4. Invasive Haemophilus influenzae serotype B 
The number of reported cases of invasive Haemophilus influenzae serotype B has 
maintained low levels in Portugal, with 5 reported cases in 2011 to 2 reported cases in 2015. 
During the same period, the total number of reports was 22, causing 3 deaths. From the total 
reported cases 11 occurred in paediatric age (6 cases – 0-4 years, 5 cases – 5-14 years), 68% 
of cases occurred in male, 32% cases in female. In the Netherlands reported number cases 
are higher than in Portugal, with 37 reported cases in 2010 to 34 reported cases in 2015. 
Although the number of reported cases are decreasing over the years, it is still a case of 
concern. From 2010 to 2015 178 cases of disease were reported, 65 reported cases occurred 
in paediatric age (55 cases – 0-4 years, 10 cases – 5-14 years), 49% of cases occurred in 
male, 51% cases in female (figure 23). 
3.4.2.5. Invasive meningococcal disease serotype C 
In Portugal as it happens in the Netherlands reported number cases of invasive 
meningococcal disease serotype C assume very low levels, notification rate per 100 000 
population in Portugal was 0.06 in 2010 and 0.04 in 2015, in the Netherlands notification rate 
was 0.06 in 2010 and 0.05 in 2015. In Portugal, from 2010 to 2015 there were 20 reported 
cases of disease, 4 cases occurred in paediatric age (1 case – 0-4 years, 3 cases – 5-14 
years), 27% of reports occurred in male, 73% in female. In the Netherlands, during this period 
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a total of 34 cases were reported, 8 cases occurred in paediatric age (0-4 years), 56% cases 
occurred in male, 44% cases occurred in female (figure 24). 
 
Figure 23. Invasive Haemophilus influenzae serotype B reported number cases per year from 2011 to 2015 in 
Portugal and from 2010 to 2015 in the Netherlands. Reported number cases in 2010 for Portugal were not available. 
 
Figure 24. Invasive Meningococcal disease serotype C reported number cases per year from 2010 to 2015 in 
Portugal and in the Netherlands. 
 
3.4.2.6. Measles 
 The number of reported cases of Measles is decreasing over the years in Portugal, with 
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47% cases occurred in male, 53% cases in female. In the Netherlands, although reported 
cases are decreasing over the years, 2010 with 15 reported cases and 2016 with 6 reported 
cases (0,9/ 100 000 in 2010 and 0,36/ 100 000 in 2016), there was a peak of reported cases 
in 2013 with 2872 reported number cases of Measles (157,33/ 100 000). From 2010 to 2016 
a total of 2872 cases were reported, resulting in one death. 2240 reported cases occurred in 
paediatric age (527 cases – 0-4 years, 1713 cases – 5-14 years), 50% cases occurred in male, 
50% cases in female (figure 25). 
 
Figure 25. Measles reported number cases per year from 2010 to 2016 in Portugal and in the Netherlands. 
 
3.4.2.7. Mumps 
In Portugal, the number of reported cases of mumps suffered slight variations over the 
years maintaining almost the same levels, from 140 reported cases of measles in 2010 to 146 
cases in 2015 (1,32/ 100 000 population in 2010 to 1,41/ 100 000 in 2015). From a total of 821 
during this five years, 584 cases occurred in paediatric age (248 cases – 0-4 years, 336 cases 
– 5-14 years), 59% cases occurred in male, 41% cases in female. In the Netherlands 
notification rate per 100 000 population is decreasing over the years, but numbers are still very 
high when compared to Portugal, with 424 reported cases in 2010 to 87 reported cases in 2015 
(2,56/ 100 000 in 2010 to 0,51/ 100 000 in 2015). A total of 1800 cases were reported between 
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2010 and 2015, 100 cases occurred in paediatric age (20 cases – 0-4 years, 80 cases – 5-14 
years), 58% cases occurred in male, 42% cases in female (figure 26). 
Figure 26. Mumps reported number cases per year from 2010 to 2015 in Portugal and in the Netherlands. 
 
3.4.2.8. Rubella 
Rubella number of reported cases has slightly increased over the years in Portugal, 
with 1 report in 2010 to 8 reports in 2016 (0,09/ 100 000 population in 2010 to 0,77/ 100 000 
in 2016). A total of 24 cases were reported between 2010 and 2016, 20 cases occurred in 
paediatric age (15 cases – 0-4 years, 5 cases – 5-14 years), 38% cases occurred in male, 
63% cases in female. In the Netherlands reported cases are very low, although in 2013 57 
cases of rubella were reported (3,40/ 100 000). A total of 62 cases were reported between 
2010 and 2016, 53 cases occurred in paediatric age (11 cases – 0-4 years, 42 cases – 5-14 
years), 57% cases occurred in male, 43% cases in female (figure 27).  
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Figure 27. Rubella reported number cases per year from 2010 to 2015 in Portugal and in the Netherlands. 
 
3.4.2.9. Diphtheria 
In Portugal from 2010 to 2014 we did not have any reported case of diphtheria. In the 
Netherlands, we had one case of diphtheria in 2012 and another in 2014 (figure 28). 
 
3.4.2.10. Tuberculosis 
 Tuberculosis notification rate is high in Portugal, ranging from 2715 reported cases in 
2010 to 2124 reported cases in 2015 (25,68/ 100 000 population in 2010 to 20,47/ 100 000 in 
2015). A total of 14742 cases of tuberculosis were reported between 2010 and 2015, 9879 
cases occurred in paediatric age (186 cases – 0-4 years, 9693 cases – 5-14 years), 66% 
reported cases occurred in male, 34% cases in female. In the Netherlands, notification rate is 
considerably lower than in Portugal, with 1068 reported cases in 2010 to 867 reported cases 
in 2015 (6,44/ 100 000 in 2010 to 5,13/ 100 000 in 2015). A total of 5554 cases were reported 
between 2010 and 2015, 263 cases occurred in paediatric age (78 cases – 0-4 years, 185 
cases – 5-14 years), 58% reported cases occurred in male, 42% cases in female (figure 29).  
In table 6, we present the reported cases and notification rate per 100 000 population, 
of selected vaccine preventable diseases, with information about age and gender of the 
individual, in Portugal and in the Netherlands by year. 
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Figure 28. Diphtheria reported number cases per year from 2010 to 2015 in Portugal and in the Netherlands. 
 
Figure 29. Tuberculosis reported number cases per year from 2010 to 2015 in Portugal and in the Netherlands. 
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Table 6. Reported cases and notification rate of selected vaccine preventable diseases with information about age and gender, in Portugal and 
in the Netherlands by year. 
 
Disease Year Portugal Netherlands 
Reported 
cases 
(N) 
Notification 
rate 
(N/100000) 
Number 
of deaths 
(N) 
Age (%) Gender (%) Reported 
cases 
(N) 
Notification 
rate 
(N/100000) 
Number 
of deaths 
(N) 
Age (%) Gender (%) 
0-4y  5-14y  Male  Female 0-4y  5-14y  Male  Female 
Hepatitis B 2010 0 0 n.d. 0 0 0 0 196 1,18 n.d. 0 0,5 79,1 20,9 
2011 1 0,01 n.d. 0 0 100 0 158 0,95 n.d. 0 0,6 77,8 22,2 
2012 8 0,08 n.d. 0 0 75 25 173 1,03 n.d. 0,6 1,7 79,2 20,8 
2013 8 0,08 n.d. 12,5 0 87,5 12,5 144 0,86 n.d. 0 1,4 74,3 25,7 
2014 19 0,18 n.d. 0 0 57,9 42,1 142 0,84 n.d. 0 0,7 74,6 25,4 
Tetanus 2010 3 0,03 0 0 0 0 100 1 0,01 0 0 0 0 100 
2011 0 0 0 0 0 0 0 6 0,04 1 0 0 66,7 33,3 
2012 3 0,03 1 0 0 33,3 66,7 2 0,01 0 0 0 100 0 
2013 1 0,01 0 0 0 100 0 1 0,01 0 0 0 100 0 
2014 2 0,02 1 0 0 0 100 0 0 0 0 0 0 0 
2015 1 0,01 0 0 0 0 100 1 0,01 0 0 0 100 0 
Pertussis 2010 14 0,13 0 100 0 57,1 42,9 3733 22,52 0 6,8 30,7 46,5 53,5 
2011 32 0,3 0 96,9 0 43,8 56,3 5447 32,7 3 5,8 35,1 46 54 
2012 237 2,25 4 91,6 4,3 46 54 12853 76,82 2 4,1 29,6 44,5 55,5 
2013 106 1,01 2 81,1 7,5 42,5 57,5 2982 17,77 1 5,7 26 44,9 55,1 
2014 74 0,71 0 91,9 2,8 47,3 52,7 8067 47,93 0 7,1 31,1 43,6 56,4 
2015 238 2,29 2 79 10,5 52,9 47,1 6178 36,55 0 5,7 30,6 41,9 58,1 
Invasive 
Haemophilus 
influenzae 
serotype B 
2010 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 37 0,22 n.d. 24,3 0 45,9 54,1 
2011 5 0,05 0 40 0 80 20 22 0,13 n.d. 27,2 4,5 31,8 68,2 
2012 4 0,04 0 25 0 100 0 27 0,16 n.d. 22,2 14,8 55,6 44,4 
2013 5 0,05 0 20 40 80 20 29 0,17 n.d. 44,8 3,4 35,7 64,3 
2014 6 0,06 2 16,7 33,3 50 50 29 0,17 n.d. 27,5 10,3 53,6 46,4 
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2015 2 n.d. 1 50 50 0 100 34 0,2 0 38,2 2,9 64,7 35,3 
Invasive 
meningococcal 
disease 
serotype C 
2010 6 0,06 n.d. 0 33,3 40 60 10 0,06 n.d. 30 0 50 50 
2011 2 0,02 n.d. 0 50 50 50 4 0,02 n.d. 0 0 25 75 
2012 4 0,04 n.d. 0 0 25 75 4 0,02 n.d. 75 0 75 25 
2013 2 0,02 n.d. 0 0 0 100 5 0,03 n.d. 0 0 60 40 
2014 2 0,02 n.d. 50 0 0 100 3 0,02 n.d. 0 0 33,3 66,7 
2015 4 0,04 n.d. 0 0 25 75 8 0,05 n.d. 25 0 75 25 
Measles  2010 5 0,47 0 0 0 60 40 15 0,9 0 20 13,3 60 40 
2011 2 0,19 0 50 0 100 0 50 3 0 8 26 52 48 
2012 7 0,66 0 42,9 0 28,6 71,4 10 0,6 0 30 0 50 50 
2013 1 0,1 0 0 0 0 100 2640 157,33 1 17,8 63,6 49,2 50,8 
2014 0 0 0 0 0 0 0 144 8,56 0 32,7 11,8 60,8 39,2 
2015 0 0 0 0 0 0 0 7 0,41 0 0 0 85,7 14,3 
2016 0 0 0 0 0 0 0 6 0,36 0 0 33,3 33,3 66,7 
Mumps 2010 140 1,32 n.d. 33,5 41,4 60,7 39,3 424 2,56 n.d. 1,9 4,1 57,6 42,4 
2011 134 1,27 n.d. 34,3 41,1 57,5 42,5 642 3,85 n.d. 0,9 5 60,9 39,1 
2012 160 1,52 n.d. 23,1 36,9 57,5 42,5 408 2,44 n.d. 0,7 4,9 57,1 42,9 
2013 159 1,52 n.d. 23,9 46,5 59,1 40,9 201 1,2 n.d. 1,5 1,5 58,2 41,8 
2014 82 0,79 n.d. 42,7 31,7 61 39 38 0,23 n.d. 0 10,5 50 50 
2015 146 1,41 n.d. 30,8 43,8 58,2 41,8 87 0,51 n.d. 0 4,6 52,9 47,1 
Rubella 2010 1 0,09 0 0 0 0 0 0 0 0 0 0 0 0 
2011 0 0 0 0 0 0 0 1 0,06 0 0 0 0 0 
2012 2 0,19 0 0 0 0 0 1 0,06 0 0 0 0 100 
2013 0 0 0 0 0 0 0 57 3,4 0 17,5 73,7 55 45 
2014 6 0,58 0 n.d. n.d. n.d. n.d. 2 0,12 0 50 0 100 0 
2015 7 0,67 0 100 0 n.d. n.d. 1 0,06 0 0 0 100 0 
2016 8 0,77 0 0 0 0 0 0 0 0 0 0 0 0 
Diphtheria 2010 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
2011 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
2012 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
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2013 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
2014 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Tuberculosis 2010 2715 25,68 n.d. 0,7 1,5 67 33 1068 6,44 n.d. 1 2,2 56 44 
2011 2609 24,68 n.d. 0,9 1 67,5 32,5 1004 6,03 n.d. 1,7 3,9 56,5 43,5 
2012 2606 24,72 n.d. 1,2 1,7 65 35 956 5,71 n.d. 2 3,2 56,4 43,6 
2013 2410 22,98 n.d. 0,9 1,2 64,2 35,8 845 5,04 n.d. 1,1 2,8 60,4 39,6 
2014 2278 21,85 n.d. 0,7 1,1 63,5 36,5 814 4,84 n.d. 1,6 4,3 61,5 38,5 
2015 2124 20,47 n.d. 0,6 1 67,1 32,9 867 5,13 n.d. 1 3,8 59,6 40,4 
n.d.: not defined. 
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3.5. Discussion 
In Portugal, vaccine coverage is above WHO recommendations of 95% vaccine coverage 
for infectious disease elimination and control, for age cohorts of newborns (2 years old), the 
national immunization program participation ranges from 96,1% to 99,1% vaccine coverage. 
Vaccination coverage for the completed schedule for DTPa is as high as 96,1%, for MMR 
97,9%, for Hib 98,7%, for MenC 97,3% and for HBV 98,3%. BCG vaccine coverage ranges 
from 99,1% to 97,5%. Since July 2016 this vaccine is no longer universally recommended, it 
is now recommended to risk groups (85). According to WHO, BCG vaccine does not prevent 
primary infection and, more importantly, does not prevent reactivation of latent pulmonary 
infection, the principal source of bacillary spread in the community, so its impact on 
transmission of Mycobacterium tuberculosis is therefore limited (86). This may explain the high 
numbers of cases of tuberculosis in Portugal (867 reported cases in 2015) and in the 
Netherlands (2124 reported cases in 2015) over the studied years, despite high vaccine 
coverage levels.  
Although we did not include Inactivated Polio Vaccine (IPV) in this study, data on the 
evaluation of NIP 2016, shows that for 2015 age cohort IPV vaccine coverage was 98% (87).  
The Netherlands has a centralized (public) vaccination system, as it happens in Portugal, 
and vaccination is free of charge. In this study, The Netherlands vaccination coverage is 
considered high but, in some cohorts, it still does not match the 95% recommended vaccine 
coverage. Other studies conducted in countries with decentralized (private) vaccination system 
such as Germany, has demonstrated moderate vaccination coverage levels with most 
traditional vaccinations at 73-80% (88), another study conducted in France demonstrates 83% 
DTPa vaccination coverage and 83% MMR vaccination coverage (89). These data suggest 
that public vaccination systems, free of charge, could have an impact on vaccination. 
In The Netherlands, HBV vaccine coverage suffered a huge increase over the studied 
cohorts, it is important to note that it was just in 2011 that HBV was introduced into the NIP 
(38), this explains HBV 19,7% vaccine coverage in 2010 cohort. In Portugal, this vaccine was 
introduced into the NIP in 1993 (90). With the introduction of this vaccine in The Netherlands, 
it is possible to observe a declining trend in hepatitis B reported number cases over the years, 
with 196 cases in 2010 to 142 cases in 2014. In Portugal, hepatitis B reported number cases 
are maintaining low levels, with the maximum of 19 reported number cases in 2014. 
In this study it is possible to observe vaccination coverage decline over the selected 
cohorts in the Netherlands, this data is in accordance with other studies published elsewhere 
(91). The cause of such decline is unknown but it has been reported to the public health 
institute to be investigated. If this trend continues, the risk of future outbreak of measles 
increases. As it is recorded in this study, in 2013 a large measles epidemic of 2640 reported 
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cases took place in The Netherlands, one person died and there were cases with severe illness 
(92). The vast majority of reported cases were among unvaccinated orthodox Protestant 
individuals (92). In Portugal, from 2014 to 2016 no cases of measles were reported. So, in 
2015 WHO declared that measles and rubella were eliminated in Portugal. Although in our 
study, from 2010 to 2016, 24 cases of rubella were reported, just 2 cases (1 case in 2014 and 
1 case in 2015) were confirmed as lab-positive cases of rubella (93–98). In 2017, 28 laboratory-
confirmed measles cases were identified in Portugal, of which 16 were unvaccinated and one 
unvaccinated teenager died (99). Measles outbreaks have been reported in Europe, such as 
in Germany, Italy, Spain (100). Mumps prevention benefits indirectly from the efforts made to 
reach the goal of eliminating measles and rubella in Europe (101). Although the number of 
cases is still far from disease elimination. In Portugal, reported cases vary from 160 (2012) to 
82 (2014), and in the Netherlands, it ranges from 642 (2011) to 38 (2014). A decreasing trend 
is observed over the years. Studies have shown that the effectiveness of mumps vaccination 
depends on the time between the first and second dose given (102).   
In Portugal, no case of diphtheria was reported since 2010, in the Netherlands just 2 cases 
of diphtheria were reported, one in 2012 and the other in 2014. Diphtheria case detection is 
strongly influenced by the availability of laboratory resources, clinical expertise and 
surveillance systems (103). And the availability of such resources seems to be unevenly 
distributed in Europe, and very few countries perform toxigenicity testing (103). On May 2015, 
Spain reported a case of toxigenic diphtheria (104). The case was a 6-year-old voluntarily 
unvaccinated boy, who died from the disease in a Barcelona hospital (104). This was the first 
case of diphtheria reported in Spain since 1986 (104).   
Cases of invasive H. influenzae disease serotype B are rare in Europe, and it has been 
reported that the disease is most common in the north of Europe (105). In Portugal, the number 
of cases is very low, from 6 cases in 2014 to 2 cases in 2015. In The Netherlands, the number 
of cases varies from 37 in 2010, to 22 in 2011. The sustained low number of serotype B cases 
reported highlights the success of immunization (105). 
The number of reported cases of tetanus in Portugal and in The Netherlands, are very low 
and shows a decreasing trend. Notification rate for tetanus is also very low in the other EU/EEA 
countries (106). According to ECDC, despite the small number of cases, tetanus is associated 
with high mortality, which could be prevented by vaccination (106). 
Invasive meningococcal disease serotype C cases are low in Portugal as in The 
Netherlands. According to ECDC, in Europe, serogroup C continues to show a decreasing 
trend and is proportionally twice as prominent in countries that do not include MenC vaccination 
in their routine NIP (107). Serogroup B is responsible for the majority of cases of invasive 
meningococcal disease, predominantly affecting the younger age groups (107). In Europe, a 
vaccine against serotype B was licensed in 2013 and was estimated to provide protection 
53 
 
against between 73% and 87% of circulating serogroup B strain (107). In some European 
countries, this vaccine was introduced in the NIP, such as in the United Kingdom (107). This 
vaccine could be an important target to the Portuguese immunization program.  
A notable increase of pertussis notification rate was observed in The Netherlands in 2012, 
according to this study 12853 cases of pertussis were reported, it represented the highest 
number of cases reported in EU/ EEA, followed by the United Kingdom (11993 reported cases) 
(108). In Portugal, 237 cases were reported in 2012, this still represents an increase from 2011 
(32 reported cases). These data highlights that vaccine preventable infectious diseases are 
still a reason of concern, and it is important to maintain the high levels of vaccine coverage to 
eliminate and control infectious diseases. 
3.5.1. Limitations 
As a limitation of this study, we did not analyse vaccination coverage per dose. Inactivated 
polio, human papillomavirus and pneumococcal 13-valent vaccines were not studied.  
It is important to note, that we analysed the reported number cases of disease, which lack 
laboratory confirmation. This means, that the presented numbers do not represent the real 
number of disease cases. The reported number cases among countries are still influenced by 
several factors, including differences in surveillance systems, historical or current vaccination 
policies, and vaccination coverage levels. 
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4. CHAPTER 4 – SYSTEMATIC REVIEW ON THE FACTORS BEHIND 
VACCINE HESITANCY AMONG PARENTS IN HIGH-INCOME 
COUNTRIES   
4.1. Introduction 
Immunisation benefits were so satisfying that today we are facing the consequences of 
its own success (7). The dramatic reduction of the incidence of these VPD during the last 
decades, contributed to the public perception that the severity of the disease and susceptibility 
to it have decreased (62). As parents have become less familiar with these diseases, they 
have become more concerned about the safety and necessity of vaccines (7). Perceived risks 
from VPD have diminished, whereas perceived risks of vaccination have increased and some 
experts identify the prevalence of concerns, fears and misinformation about vaccines as an 
indication of declining confidence in vaccines (109,110). It has been reported that in recent 
years, vaccination has declined in many regions of the world, especially in cases such as the 
combined Measles, Mumps and Rubella (MMR) vaccination (58). 
Strategic Advisory Group of Experts (SAGE) working group defines vaccine hesitancy 
as a behaviour, influenced by a number of factors including issues of confidence (do not trust 
vaccine or provider), complacency (do not perceive vaccine’s value or need), and convenience 
(access) (57). Vaccine-hesitant individuals are an heterogeneous group who hold varying 
degrees of indecision about specific vaccines or vaccination in general (57). They may accept 
all vaccines but remain concerned about it, some may refuse or delay some vaccines, but 
accept others; some individuals may refuse all vaccines (57).  
Evidence of vaccine-hesitancy trend comes indirectly from several sources, including 
studies showing that parents are more often requesting vaccine exemptions to school entry 
requirements and that providers perceive parental vaccine refusal as being more common than 
in the past (111). 
The behaviour of vaccine-hesitant individuals is complex, and determinants of 
hesitancy are highly variable across time, place and vaccine (112). H. Larson and Karafillakis 
literature review identifies three main cathegories of determinants for vaccine hesitancy; 
contextual (conspiracy theories, religious fatalism), individual and group influences (vaccine 
safety, lack of information, low risk/ severity of disease, vaccines not effective, etc) and vaccine 
and vaccination specific issues (no medical need, access, finantial costs) (113). Vaccine safety 
was the vaccine hesitancy determinant more frequently recorded in the literature (113). 
The WHO SAGE on Immunization has recognized the global importance of vaccine 
hesitancy as a growing problem (114). Several studies identify vaccine hesitancy factors and 
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strategies for addressing vaccine hesitancy from a global perpective (57,114,115). Country or 
region specific studies on vaccine hesitancy are as well available in the literature (116,117).  
4.2. Aims 
This systematic literature review aims investigate and analyse parents/legal guardians 
with children aged between birth and 18 years old reasons and beliefs for not vaccinating their 
child, delaying or doubting of one or more vaccines included in the National Immunization 
Program (NIP) in high-income countries. 
This result can be used to create strategies intended to reduce vaccine hesitancy and 
consequently, increase vaccine coverage. 
4.3. Methods 
4.3.1. Eligibility criteria 
PICO’s methodology was used in this study to define the population, intervention, 
comparator and outcomes of the study. 
4.3.1.1. Type of study 
Included studies were observational and qualitative studies respectively cohort studies, 
cross-sectional studies, focus group, case studies. 
Commentary, personal reflection, news, policy and profiles, reports, recommendations, 
editorials, literature review, cost-effectiveness, economic, effectiveness, efficacy and 
randomized controlled trial studies were excluded from the systematic review.  
4.3.1.2. Population 
Parents/Legal guardians with children aged between birth to eighteen years old, living 
in a high-income country and manifesting immunization doubts, refusal or alternative 
vaccination schedule other than the recommended one, against one or more vaccines included 
in the NIP of the living country.  
Health professional/health care provider/physician beliefs about immunization were 
excluded from the study. 
4.3.1.3. Intervention  
Qualitative intervention study included semi-structured interviews, interviews, focus 
groups and surveys. 
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4.3.1.4. Comparator 
Parents/ Legal guardians with children aged between birth to eighteen years old, living 
in a high-income country, which comply with immunization, and vaccinate their children 
according to NIP. 
4.3.1.5. Inclusion and exclusion criteria  
Table 7. Inclusion and exclusion criteria of the systematic review.  
         Inclusion criteria         Exclusion criteria 
Parental/ legal guardian, perception/ 
behaviour towards immunization studies; 
Population study is a health care provider/ 
practitioner/ physician/ health professional; 
Publications between 2006 and 2017; The subject of the intervention is pregnant 
women; 
High-income countries (classification from 
The World Bank (114)); 
HPV and seasonal influenza vaccines; 
All National Immunization Programs 
implemented in high-income countries; 
Not related to vaccine hesitancy beliefs/ 
reasons; 
All vaccines and vaccine combinations 
included in the NIP of the studied country/ 
region. 
Study about the disease itself and do not 
present parent perception toward 
vaccination; 
Language: English and Portuguese; Catch-up campaign Study;  
 New vaccine implemented in NIP; 
Non-human species study; 
Study about vaccine coverage and do not 
present parent perception toward 
vaccination; 
Population study is a minority community; 
Children with medical exemption; 
Do not present reasons to justify parental 
vaccine hesitancy. 
 
4.3.2. Information sources 
The systematic literature search was conducted in February 2017, databases included 
were PubMed, Web of Science and Science Direct. In this search, the limits used were 
publications from 2006 to 2017, in Portuguese and English languages and in the human 
species.  
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4.3.3. Search 
Search keywords were predefined (table 6).  
Table 8. Keywords applied to the systematic review search. 
 
Vaccin* 
Immunis* 
Immuniz* 
 
AND 
 
Attitude 
Behav* 
Belief 
Accept* 
Confidence 
Doubt 
Distrust 
Exemption 
 
Choice 
Hesitanc* 
Concern 
Trust 
Perception 
Anti-vaccin* 
Antivaccin* 
Uptake 
Movement 
AND Child* 
Paediatric 
 
NOT HIV 
HPV 
Pregnan* 
 
Pubmed search: ((((vaccin* OR immunis* OR immuniz*)) AND (attitude OR behav* OR 
belief OR accept* OR confidence OR doubt OR distrust OR exemption OR choice OR 
hesitanc* OR concern OR trust OR perception OR anti-vaccin* OR antivaccin* OR uptake OR 
movement)) AND (child* OR paediatric)) NOT (hiv OR hpv OR influenza OR pregnan*) 
4.3.4. Study selection  
Results were collected and duplicates were removed. Eligibility criteria were applied to 
the remaining articles by one reviser. In a stepwise methodology, consisting on tree distinct 
phases, title screening, abstract screening and full text analysis. EPPI-Reviewer 4 tool was 
used for that purpose. Studies were eligible for inclusion in the systematic review if they 
reported parents/ legal guardians of children (≤18 years old), living in a high-income country 
(according to The World Bank classification (118)), reasons/ motivations/ beliefs for doubting 
immunization, changing the recommended vaccine schedule or refusing vaccinate their child 
against one or more vaccine preventable disease included in NIP of their living country. 
4.3.5. Data collection process 
After study selection, data was collected and analysed using codification and synthesis 
method for qualitative data.  
Information extracted from the studies included details on vaccine hesitancy factors/ 
beliefs/ motivations, this text was codified in a descriptive way so that we could create final 
analytical themes. The qualitative software ATLAS.ti version 7.5 (Scientific Software 
Developments) was used to assist in data analysis. 
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4.3.6. Risk of bias  
The Effective Public Health Practice Project (EPHPP) quality assessment tool was 
applied to assess and evaluate the risk of bias of each individual study.  
4.3.7. Synthesis of results 
Statistical analysis was performed with resource to SPSS software (version 24.0). 
Absolute and relative frequencies of the total number of vaccine hesitancy themes found 
throughout the selected articles and the relative frequency of articles that exhibit one vaccine 
hesitancy factor were calculated. 
4.4. Results 
Keyword based search identified a total of 19308 articles (PubMed – 5041 articles, Web of 
Science – 3698 articles, Science Direct – 10569 articles). After duplicates removal, 17323 
articles were analysed by title and 422 articles by abstract using EPPI-Reviewer 4 tool. 101 
articles were included for a full-text review considering inclusion and exclusion criteria. From 
these articles, 74 studies were excluded based on the exclusion criteria. A total of 27 articles 
were included for analysis, published between 2006 and 2016 and comprising a total of 54786 
participants (range: 20 – 18488) (figure 30). 
The characteristics of each study included in the systematic review is set out in table 9. 
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Figure 30. Flow diagram of included studies in the systematic review, adapted from (119). 
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The majority of articles focused on childhood vaccines in general (n=19) and were not 
specific to one vaccine, vaccine specific studies were mostly about MMR vaccine (n=6). Other 
articles focused on HBV vaccine (n=2). Most studies were retrospective, parents were 
recruited, and their attitudes and beliefs towards immunization were assessed, after they had 
made their vaccination decision. The vaccine hesitancy beliefs/ factors were typically assessed 
subjectively with resource to parent-reported intervention or behaviour. Study design included 
cross-sectional study (n=24), cohort study (one group pre- and post) (n=2) and case-control 
study (n=1). Out of the 27 articles, the majority were from the United States (n=14), followed 
by United Kingdom (n=5), Switzerland (n=2), The Netherlands (n=2), Italy (n=2), Spain (n=1) 
and Canada (n=1). 
Vaccine hesitancy factors/ beliefs/ motivations included in each of the 27 selected articles 
were codified in 20 different themes addressing factors/ reasons/ motivations/ beliefs for 
parental vaccine hesitancy in high income countries (table 10). For this purpose, one article 
can refer to more than one theme, we do not take into account the number of times one article 
records the same theme. Throughout the selected articles we could identify 199 themes, note 
that although we just selected 20 different themes, the same theme can be found in different 
articles. 
Vaccine safety was the most reported reason of vaccine hesitancy amongst all factors. It 
was reported in all (n=27) of the included articles. It was followed by low risk perception/ 
severity of disease (n=19), overloading immune system (n=16), negative exposure to media/ 
people opinion (n=16), vaccines link to autism/ chronic diseases (n=15), the remaining factors 
are presented in table 10. The least factors reported by parents for vaccine hesitancy were 
religious beliefs (n=2), services/ accessibility (n=3) and trauma of immunization process (n=3). 
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Table 9. Characteristics of studies included in the systematic review. 
 
Author/ year of 
publication 
 
Country Aim Population of interest Sample 
size 
Data collection 
period 
Study design Intervention Vaccination 
of interest 
Risk of 
bias 
A. Smith, Yarwood, 
and Salisbury 2007 
UK To demonstrate how attitudes in relation to 
MMR have evolved over the last 10 years 
incorporating the periods of time before, during 
and after the height of the MMR controversy 
within the UK. 
 
Mothers of children aged less 
than 36 months. 
1016 October and 
November 2006 
Cross-sectional 
study 
Interview MMR Moderate 
Bigham et al. 2006 Canada - 
British 
Columbia 
To evaluate hepatitis B immunization coverage 
among the first six-month cohort of eligible 
infants in the province outside of the 
Vancouver-Richmond health region and to 
assess parent/guardian behavioural and 
attitudinal determinants of HB immunization. 
 
Parents of children (15 months 
to 2 years) 
487 October 2002 
and January 
2003 
Cross-sectional 
study 
Survey HBV Moderate 
Blaisdell et al. 2016 USA - Maine To explore perceived and constructed personal 
judgments about the risks and uncertainties 
associated with vaccines and vaccine 
preventable diseases and how these subjective 
risk judgments influence parents’ decisions 
about childhood vaccination. 
 
Parents of children  
(0 to 8 years), residing in the 
greater Portland, Maine, area. 
42 not defined Cross-sectional 
study 
Focus group Childhood 
vaccines 
Moderate 
Borràs et al. 2009 Spain - 
Catalonia 
To investigate parental knowledge of paediatric 
vaccines and vaccination in Catalonia. 
 
Parents of children 
born in October 2001 in 
Catalonia. 
630 October 2003 
and September 
2004 
Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
Brown et al. 2011 UK To develop and validate a scientiﬁcally robust 
and practically feasible MMR attitudes 
measurement instrument, aiming to overcome 
methodological limitations currently inhibiting 
the evidence base through evidence-based 
item selection, psychometric validation, and 
objective outcome assessment. 
 
Parents of children (4 to 16 
years). 
535 May and 
December 2009 
Cross-sectional 
study 
Survey MMR Moderate 
Brown et al. 2012 UK To obtain an up-to-date, comprehensive and 
methodologically robust picture of general 
factors underlying parents’ decision-making 
about the first dose of MMR. 
 
Parents of children 11 months 
and 3.5 years. 
24 June 2008 and 
March 2009 
Cross-sectional 
study 
Semi-
structure 
interviews 
MMR Moderate 
Coniglio et al. 2011 Italy - Sicily To explore the issues surrounding parental 
acceptance or non-acceptance of the 
recommended vaccinations for children. 
 
Parents of children aged 3-5 
years of day-care centres in 
Sicily. 
1218 October and 
December 2008 
Cross-sectional 
study 
Survey Childhood 
vaccines 
Strong 
Dempsey et al. 
2011 
USA To describe national patterns of alternative 
vaccination schedule use and the potential 
“malleability” of parents’ current vaccination 
schedule choices. 
 
Parents, stepparents, or 
guardians of children 6 months 
to 6 years of age. 
748 May 2010 Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
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Fadda et al. 2016 Italy To gain insights from parents residing in a low 
measles-mumps-rubella (MMR) uptake area on 
what constitutes feelings of empowerment in 
the decision they have to make on their child’s 
MMR vaccination. 
 
Parents with at least one child 
aged less than 1 year or for 
whom an MMR vaccination 
decision was still pending, and 
be residing in Italy. 
28 March and May 
2015 
Cross-sectional 
study 
Focus group MMR Moderate 
Freed et al. 2010 USA To characterize the current prevalence of 
parental vaccine refusal and specific vaccine 
safety concerns and to determine whether such 
concerns were more common in specific 
population groups. 
 
Parents of children who were 
aged 17 years. 
1552 January 2009 Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
Gross et al. 2015 Switzerland To understand the influence of parents’ 
emerging views linked to “natural and healthy” 
lifestyles on their decision regarding childhood 
vaccination. 
 
Parents of children (0-16) who 
had either been immunized 
incompletely, partially or who 
had not been immunized at all. 
32 2011 Cross-sectional 
study 
Semi-
structure 
interviews 
Childhood 
vaccines 
Moderate 
Harmsen et al. 2013 The 
Netherlands 
To attain more insight into the factors behind 
immunization decisions among Dutch parents. 
 
Parents with children (0–4 
years old). 
60 November and 
December 
2011. 
Cross-sectional 
study 
Focus group Childhood 
vaccines 
Moderate 
Hontelez et al. 2010 The 
Netherlands 
To identify the determinants of HBV vaccine 
acceptance and explain the large difference 
between DPT-IPV-Hib and HBV vaccine 
coverage among the population eligible for HBV 
vaccination in the NIP. To determine the 
attitude towards universal HBV vaccination 
among parents of HBV eligible and non-HBV-
eligible children. 
 
Parents of children born in 
2003–2005 and registered in 
the national vaccination 
registration database 
‘Praeventis’. 
198 not defined Cross-sectional 
study 
Survey HBV Moderate 
Kennedy et al. 2011 USA To examine the notions of confidence in 
vaccines and hesitancy about their use, building 
on recent efforts to understand parents’ beliefs 
and behaviours related to routinely 
recommended childhood immunizations. 
 
Parent or guardian of one or 
more children age six or 
younger. 
376 2010 Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
Kennedy, Basket, 
and Sheedy 2011 
USA To describe the vaccine-related attitudes, 
concerns, and information sources of US 
parents of young children. 
 
Parents with at least 1 child 
aged 6 years or younger. 
475 August and 
september 2009 
Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
Lieu et al. 2017 USA To describe parents’ (1) perspectives on how to 
improve the process, (2) rationales for use of 
nonstandard vaccination approaches, and (3) 
reactions to hypothetical alternatives to the 
standard schedule. 
 
Parents of children (0 to 5 
years). 
1222 not defined Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
Luthy et al. 2012 USA - Utah To explore personal beliefs of parents living in 
Utah, who exempted their children from 
receiving vaccinations. 
 
Utah parents seeking to 
exempt 
a child from vaccinations for 
personal reasons. 
287 August 2007 
and May 2008 
Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
Luthy, Beckstrand, 
and Callister 2010 
USA - Utah To determine why parents in a Utah community 
hesitated in immunizing their children. 
 
Parents of under-immunized 
children in the county health 
department and local paediatric 
and family practice offices. 
86 not defined Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
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Niederhauser and 
Markowitz 2007 
USA - 
Hawaii 
To explore the barriers to immunizations in 
parents whose children are not fully immunized 
by age 2. 
 
Parents of 2- to 4-year old 
children who were not fully 
immunized at age 24 months. 
64 December 2003 
and july 2004 
Cross-sectional 
study 
Focus group Childhood 
vaccines 
Moderate 
P. J. Smith et al. 
2011 
USA To evaluate the association between parents’ 
beliefs about vaccines, their decision to delay or 
refuse vaccines for their children, and 
vaccination coverage of children at aged 24 
months. 
 
Households that have children 
aged 19–35 months. 
11206 2009 Cross-sectional 
study 
Survey Childhood 
vaccines 
Moderate 
Pearce et al. 2008 UK To estimate uptake of the combined measles, 
mumps, and rubella vaccine (MMR) and single 
antigen vaccines and explore factors 
associated with uptake and reasons for not 
using MMR. 
 
Parents of children born in the 
UK, 2000 – 2002. 
14578 not defined Cohort study 
(one group pre-
and post) 
Interview MMR Moderate 
Salmon et al. 2009 USA - 
Wisconsin 
To determine differences in vaccine attitudes, 
beliefs, and information sources among parents 
of children with nonmedical exemptions to ≥1 
vaccines compared with parents of fully-
vaccinated children in Wisconsin. 
 
Parents of children with 
nonmedical exemptions 
(cases) and parents of fully-
vaccinated children (controls). 
963 not defined Case-control 
study 
Survey Childhood 
vaccines 
Moderate 
Samad et al. 2006 UK To analyse the reasons given by mothers for 
partial and no immunisation in infancy in a 
nationally representative study. 
 
Parents of children born in the 
UK, 2000 - 2003 
18488 not defined Cohort study 
(one group pre-
and post) 
Interview Childhood 
vaccines 
Moderate 
Senier 2008 USA To understand parents’ beliefs on risk 
perception and trust in the context of parental 
decision making about vaccines. 
 
Parents of children (18 months 
to 16 years). 
20 August and 
November of 
2004. 
Cross-sectional 
study 
Semi-
structure 
interviews 
Childhood 
vaccines 
Moderate 
Wang, Baras, and 
Buttenheim 2015 
USA - 
Philadelphia  
To understand how parents, make vaccination 
decisions, how their vaccine concerns translate 
into deviations from the recommended 
schedule despite general acceptance of 
vaccines, and how they view others’ decisions 
not to vaccinate. 
 
Parents of children (18 months 
to 6 years) in an upper-middle 
class neighbourhood in 
Philadelphia. 
25 July and 
September 
2010 
Cross-sectional 
study 
Semi-
structure 
interviews 
Childhood 
vaccines 
Moderate 
Weiss, Schröpfer, 
and Merten 2016 
Switzerland 
- Aargau 
To identify distinct patterns of attitudes towards 
or against measles vaccination through Latent 
Class Analysis (LCA) in a sub-sample of 
mothers living in the canton of Aargau in 
Switzerland. 
 
Parents of young children 
below 36 months of age. 
189 2011 Cross-sectional 
study 
Survey MMR Moderate 
Wheeler and 
Buttenheim 2013 
USA To examine factors associated with a parent’s 
intended choice of vaccine schedule using 
medical record data routinely collected during a 
well-baby visit at a private paediatric practice. 
 
Parents of infant less than one 
year of age at the time of 
vaccine counselling. 
237 December 2009 
and April 2011 
Cross-sectional 
study 
Medical 
record data 
assessment 
Childhood 
vaccines 
Moderate 
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Table 10. Analysed theme factors behind vaccine hesitancy in the systematic review. 
 
Factors behind vaccine hesitancy 
Absolute 
frequency 
(N) 
Relative 
frequency 
(%)  
References 
Vaccine safety 27 13,57% 
(53,56,62,64,110,120–141) 
Low risk perception/ severity of 
disease 
19 9,55% 
(53,64,110,120–122,124–
126,128,131,132,134–
139,141) 
Negative exposure to media/ people 
opinion 16 8,04% 
(53,62,64,121,122,124,127,1
29–132,135–137,140,141) 
Overloading immune System 
16 8,04% 
(64,110,120–
122,127,128,130,131,134–
139,141) 
Vaccines link to autism/ chronic 
diseases 15 7,54% 
(62,64,110,121,124,127–
132,135,136,139,140) 
Immunization perceived as negative 
on the immune system 13 6,53% 
(64,120,122,125,126,128,129
,131,135–137,139,141) 
Vaccine ingredients 
11 5,53% 
(64,110,121,128,130,131,134
,136,137,139,141) 
Alternative prevention methods 
10 5,03% 
(64,120,123,124,127,129,131
,135–137) 
Previous negative experiences 
10 5,03% 
(64,120,122–
124,128,132,135,136,141) 
Vaccine effectiveness/ utility 
10 5,03% 
(56,64,120,127,130–
132,134–136) 
Lack of appropriate research 
8 4,02% 
(64,110,120,122,132,136,139
,141) 
Mistrust in government and 
pharmaceutical companies 8 4,02% 
(124,126,129,131,136,137,13
9,141) 
Mistrust in health professionals 
7 3,52% 
(121,124,129,131,136,137,14
0) 
Disease are beneficial 
6 3,02% 
(64,120,122,124,131,136) 
Medical reasons 6 3,02% 
(62,64,121,123,127,141) 
Parental issues 5 2,51% 
(122,123,127,135,141) 
Parental knowledge 4 2,01% 
(129,138,140,141) 
Services/ accessibility 
3 1,51% 
(123,135,141) 
Trauma of immunization process 3 1,51% 
(138,139,141) 
Religious beliefs 2 1,01% 
(125,141) 
Total 199a 100,00% 
(53,56,62,64,110,120–141) 
 
a Interventions could address more than one determinant of vaccine hesitancy. 
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4.4.1. Vaccine safety 
All studies included in the systematic review cited vaccine safety as one of the factors 
leading to vaccine hesitancy, it represents 13,57% of all recorded themes. Parental concerns 
about the safety of vaccination includes, vaccines perceived as an unnatural substance 
responsible for weakening the organism, causing mild to serious side effects/ adverse events, 
including serious diseases and long-term side effects. Safety concerns may be associated just 
to some vaccines or to vaccines in general. 
4.4.2. Low risk perception/ severity of disease 
According to this study, low risk perception is the second most recorded theme (9,55%). 
Most parents perceive vaccine preventable diseases as mild illnesses, not severe if contracted 
and easily treated. Most believe that the experience of contracting the illness and its recovery 
is associated with progress in the child’s development, so that some parents prefer natural 
immunity over vaccination. Vaccine hesitant parents consider VPD rare in their living high-
income country, they believe their children are not at risk of contracting a communicable 
disease. 
4.4.3. Negative exposure to media/ people opinion 
Conflicting risk information and negative stories are presented by various sources as the 
media, internet web sites and Facebook pages. It may create parental indecisions regarding 
immunization. People in the social environment, as friends and family, may influence the 
parental choice to delay or refuse vaccination.  
4.4.4. Overloading immune system 
One of the most reported parental concerns is administering multiple vaccines at once 
at a young age (8,04%). Some parents fear that administering combined vaccines could 
overload or overwhelm the child’s immune system. 
4.4.5. Vaccines link to autism/ chronic diseases 
Some parents believe that vaccination may cause learning disabilities such as autism in 
healthy children, neurological conditions or brain hyper-inflammatory response. They believe 
that vaccines may cause chronic diseases as seizures, attention deficit with hyperactivity 
disorder, diabetes, asthma or immune system problems. 
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4.4.6. Immunization perceived as negative on the immune system 
According to parental opinion, immunization is generally perceived as artificial, 
unnecessary and it is seen as a negative intrusion into the development of a natural immune 
system, which may weaken and damage the child’s immune system. 
4.4.7. Vaccine ingredients 
There are parental concerns about unsafe ingredients which some vaccines contain or 
have contained. Such as thimerosal, aluminium, potential allergens, mercury, heavy metals, 
adjuvants and preservatives, neurotoxins, formaldehyde and DNA from other animals. 
4.4.8. Alternative prevention methods 
Many parents argue that the strength of the immune system can be built up by healthy 
environment, such as good nutrition, raise children in a small-scale home, part-time work, 
exposure to low-level pathogens, non-smoking environment with access to excellent medical 
care, isolation from geographic areas of disease and avoidance of traveling. Breastfeeding 
was mentioned as a sufficient measure to protect infants. Most of parents who held these 
beliefs showed a particular preference for homeopathy, naturopathy and chiropractors. 
4.4.9. Previous negative experiences 
Parents’ previous experiences of adverse events following immunization that have occur 
to themselves as a child, or to their own children, are reported as an important barrier to 
immunization. Parental knowledge on these events, stories of negative experiences towards 
immunization, or medical problems due to an AEFI, in a family member, friends or other social 
environment are as well cited in this study.  
4.4.10. Vaccine effectiveness/ utility 
In parents’ opinion, vaccination is seen with a lower quality of acquired immunity 
compared to the natural means, the uncertainty about the body reactions to it, and it’s artificial 
timing are of a big concern to these parents. Some vaccines are defined by them, as 
unnecessary and not sufficiently effective. 
4.4.11. Lack of appropriate research 
Many parents argue that vaccines are administered to the child without really knowing 
what it triggers. Scientific research is seen as inadequate, they believe that vaccines are not 
tested enough for safety and that there are no long-term studies of vaccines. 
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4.4.12. Mistrust in government and pharmaceutical companies 
Parental concerns include the belief that childhood vaccination is of financial interest to 
other parties, particularly pharmaceutical industries and the government. Some parents 
express scepticism about the role of pharmaceutical companies in drug safety. 
4.4.13. Mistrust in health professionals 
Some parents concern about the trustworthiness of the border public health network. 
These parents do not trust clinicians’ reassurances about vaccine safety or do not perceive 
the paediatrician to be competent.   
4.4.14. Diseases are beneficial 
Childhood diseases are not perceived as a threat but as part of the natural way to 
strengthen the organism and to acquire natural immunity. Parents associate the experience of 
illness and recovery to progress in the child’s development, they believe that contracting the 
disease provides superior protection against infectious diseases than immunization. 
4.4.15. Medical reasons 
Some parents alter vaccine schedule due to the child being sick, unwell, with respiratory 
infections or in the hospital at the time of the appointment. Medical reasons cited by these 
parents included chicken pox, salmonella infection, diabetes, eczema, allergy to dairy foods or 
being premature. Mild conditions such as colds or teething problems were cited as well. 
4.4.16. Parental issues 
Some parents confess that they are unable to keep appointment due to complex 
schedules and work, administrative difficulties (costs of transportation, health insurance 
services), transportation problems, or just because it is complex to get the children to the clinic. 
Parental substance abuse, neglecting their children, lack of motivation to get the child to the 
clinic, forgetting the appointment and parental lack of personal organization are among the 
reasons why parents do not get to the clinic. 
4.4.17. Parental knowledge 
Some parents expressed doubts about vaccination due to lack of information, personal 
low perceived competence to decide whether to vaccinate, misunderstanding the importance 
of immunization, and a small proportion of parents were unaware of NIP.  
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4.4.18. Services/ accessibility 
Parents reported problems with health services and accessibility, such as availability of 
appointments and vaccines, and no accommodations for lost vaccination records. 
4.4.19. Trauma of immunization process 
The trauma of the immunization process for both parent and/ or child is among the cited 
reasons for hesitancy. Some parents confessed their fear over needles and showed their 
concern over the painful process of administering multiple injections to their children. 
4.4.20. Religious beliefs 
Religious beliefs were cited as a barrier to immunization. 
4.5. Discussion 
The qualitative systematic review preformed in this study identified parent’s reasons/ 
motivations/ beliefs for doubting immunization, changing the recommended vaccine schedule 
or refusing vaccinate their child. The majority of studies were conducted in the United States 
and in the United Kingdom. Leask et al. identified a spectrum of parental attitudes on 
immunization and developed five groups of parents. These include unquestioning acceptors, 
cautious acceptors, hesitant parents, late or selective acceptors, and those who refuse all 
vaccines (142). A variety of factors were identified as being associated with vaccine hesitancy, 
each factor is complex and it can vary across time, place and vaccine type (57).  
In this study, we can identify parent-specific characteristics, vaccine factors and disease 
factors that lead to vaccine hesitancy. Vaccine factors include vaccine safety, immunization 
perceived as negative on the immune system, vaccines link to autism, immune system 
overload, vaccine ingredients, vaccines effectiveness and utility and lack of appropriate 
research on vaccine development. Vaccine safety was the most recorded factor of vaccine 
hesitancy throughout studies, it was recorded in all the 27 studies included in the systematic 
review. This data is consistent with other studies addressing vaccine hesitancy (113,143). In 
Larson et al. study, the most common determinant of vaccine hesitancy in Europe was the 
concern or fear about vaccine safety. Which may include many specific beliefs, but is overall 
a problem of risk perception (113). Kestenbaum and Feemster study argues that parental 
immunization decision is influenced by their perceived risk of vaccine preventable diseases. 
As long as vaccines continue to be successful, the risk of obtaining a vaccine preventable 
disease may not motivate parents to immunize their children. Instead, parents are more 
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focused upon vaccine safety and raise concerns about potential short-term and long-term side 
effects (144). 
Disease factors include low risk perception and severity of disease and the belief that 
diseases are beneficial. Parents who refuse vaccination believe that side effects of vaccines 
are more severe than the disease itself. They believe that their child is not susceptible to the 
VPD, so they are more willing to take the risk of being infected by the disease than vaccinating 
their children due to fear of severe side effects. 
Dube et al. study outlines that a wide variety of parent-specific characteristics such as past 
experiences with health services, family histories, feelings of control, friends influences, can 
impact the decision-making process regarding vaccination (145).  
In this study, parent-specific characteristics include negative exposure to media or to other 
people opinion, mistrust in health professionals, government and pharmaceutical companies, 
previous negative experiences, religious beliefs, alternative prevention methods, medical 
reasons, trauma of immunization process, availability of appointments and vaccines, parental 
issues and parental knowledge. Negative exposure to media is recorded in 16 out of the 27 
studies included in this review. According to Dube et al., the internet has offered an opportunity 
for anti-vaccination activists diffuse their message, negative stories about vaccine safety in the 
news and on television correlate with increased incidence of vaccine preventable diseases 
(145).  
4.5.1. Limitations  
The systematic review may be subject to several limitations, the study selection and 
coding was performed by one single author, this may lead to interpretation bias.  
The qualitative design nature of the studies included in the systematic review was 
advantageous in allowing in-depth exploration of participants’ perceptions. However, most 
findings are contingent on retrospective self-report, which can be unreliable and subject to 
recall and interpretive bias. Thus, it may be subject to social desirability bias, parents may be 
compelled to give a socially expected answer. The cross-sectional design means that we 
cannot draw conclusions about causality, it is not known if the subject’s attitudes and concerns 
preceded or followed his behaviour. Most of the studies employed retrospective design in 
which attitudes were measured after vaccination was received. Participants who agreed to 
participate were probably more receptive to preventive actions than the general population. 
Some studies included in this review include potential for non-response bias. 
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5. CHAPTER 5 – CONCLUSIONS AND FUTURE RESEARCH 
 
Adverse drug reaction reporting to vaccines in the Portuguese paediatric population is 
slightly decreasing over the years, accounting for 6% of the total ADR received by the National 
Pharmacovigilance System. The system organ class most frequently involved was general 
disorders and administration site conditions, followed by injury, poisoning and procedural 
complications. From the total ADR reports in this study, 55,33% adverse reactions were 
considered serious, this was a lower value comparing this data to the total number of serious 
cases of ADR reports concerning all medicines in Portugal during the same period (74.43%). 
The ADR underreporting is an important issue, which difficult the real risk/ benefit 
assessment of any medicine, including vaccines. It is difficult to show in this study the real 
picture of ADR reporting to vaccines due to the well-known underreporting rate, but we 
estimate that a significant percentage is missing. It is of the utmost interest in terms of public 
health to improve the spontaneous ADR reporting, although our national authorities and 
pharmacovigilance system have hugely improved in the last decades, we have still a 
considerable work to do. It is necessary to create better measures to improve the voluntary 
adhesion of health professionals in the assessment of drug safety, and to encourage the 
patient (or its legal guardian in the vaccine context), to report their adverse events, since these 
ones will benefit the most of the risk assessment of medicines. 
Vaccination coverage in Portugal is very high, and it is increasing over the years. In 
contrast, in The Netherlands vaccination coverage does not comply with the 95% vaccine 
coverage recommended by WHO, for all vaccines, and it is been reported that vaccine 
coverage is decreasing in the past years. The vaccine coverage difference between these two 
high-income European countries may be a major reason for the diseases outbreaks felt in The 
Netherlands. Comparing Portuguese vaccine preventable disease cases to The Netherlands 
cases, we can observe a huge difference. In Portugal, vaccine preventable disease cases in 
the paediatric population is consistently lower than in The Netherland. 
Parental risk perception of adverse drug reactions to vaccines is playing an important role 
on parental compliance with the national immunization program in high-income countries, 
which may lead to vaccine hesitancy or vaccine refusal. Although at this moment, in Portugal, 
we do not have records of vaccine hesitancy it is important to predict such actions.  
Vaccination has shown its incredible results in the control of several diseases, our national 
immunization program distributes the included vaccines for free, it is available to any citizen. 
It is our responsibility to vaccinate our children in order to maintain high vaccination coverage 
to avoid disease outbreaks and to protect our population from the well-known effects of this 
devastating diseases. Although vaccine administration is not mandatory in our country, we 
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must consider the long-term effects of our decisions, and not only the short or medium-term 
effects which adverse drug reaction to vaccines represent. It is a civil duty to maintain the 
success of our national immunization program, and the safety of our population. 
For future studies it would be of a major interest to analyse vaccination decision making in 
the Portuguese population, investigate the proportion of vaccine hesitant parents in the 
community and their main hesitancy motivations.  
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